<?xml version="1.0" encoding="UTF-8"?>
<projectSnippetsTree>
 <snippetsTree>
  <snippets file="4-part\PMC7171471\results\search\drugs\results.xml">
   <result pre="in Laleh hospital, all flu A positive individuals routinely received" exact="oseltamivir" post="(Tamiflu) 120 mg for adults and 60 mg for"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="4-part\PMC7173238\results\search\drugs\results.xml">
   <result pre="HIV-1 (Clouser et al., 2010)HIV-1 – synergy in combination with" exact="gemcitabine" post="(Clouser et al., 2010)HIV-1 – synergy in combination with"/>
   <result pre="(2010); (Clouser et al., 2012)HIV-1 – synergy in combination with" exact="decitabine" post="(Clouser et al., 2010)MuLV (Clouser et al., 2012)HIV-2 (Beach"/>
   <result pre="et al., 2015; Zhang et al., 2017)Enteroviruses – synergy with" exact="ribavirin" post="(Kang et al., 2015)Rhinoviruses (Song et al., 2017)HCV (Beran"/>
   <result pre="anti-inflammatory properties (Van Linthout et al., 2018) Tenofovir disoproxil Acyclic" exact="adenosine" post="nucleotide analogue HIV (2001)HBV (2008) Tenofovir alafenamide Acyclic adenosine"/>
   <result pre="Acyclic adenosine nucleotide analogue HIV (2001)HBV (2008) Tenofovir alafenamide Acyclic" exact="adenosine" post="nucleotide analogue HBV (2016)HIV (several combination, see Table 2)"/>
   <result pre="analogue HSV (1980) Metastatic colorectal cancer (2015) in combination with" exact="tipiracil" post="Mycoplasma pneumonia (Sun and Wang, 2013) Valaciclovir Acyclic guanosine"/>
   <result pre="Approved nucleos(t)ide inhibitors of HBV polymerase include lamivudine, adefovir, telbivudine," exact="entecavir" post="and tenofovir. Two of them, lamivudine and tenofovir, exhibit"/>
   <result pre="include lamivudine, adefovir, telbivudine, entecavir and tenofovir. Two of them," exact="lamivudine" post="and tenofovir, exhibit multi-target activity and are also approved"/>
   <result pre="of the pentose ring. Tenofovir is an acyclic analogue of" exact="adenosine" post="5′-monophosphate and is marketed in the form of two"/>
   <result pre="5′-monophosphate and is marketed in the form of two prodrugs:" exact="tenofovir" post="disoproxil (TDF, Viread) and tenofovir alafenamide (TAF, Vemlidy). The"/>
   <result pre="the form of two prodrugs: tenofovir disoproxil (TDF, Viread) and" exact="tenofovir" post="alafenamide (TAF, Vemlidy). The roles of the two prodrugs"/>
   <result pre="by De Clercq (De Clercq, 2018). The tendency to substitute" exact="tenofovir" post="disoproxil with tenofovir alafenamide in both anti-HIV and anti-HBV"/>
   <result pre="(De Clercq, 2018). The tendency to substitute tenofovir disoproxil with" exact="tenofovir" post="alafenamide in both anti-HIV and anti-HBV treatment has been"/>
   <result pre="have shown that this drug is significantly more effective than" exact="lamivudine" post="and less likely to cause resistance. Moreover, telbivudine has"/>
   <result pre="effective than lamivudine and less likely to cause resistance. Moreover," exact="telbivudine" post="has some pleiotropic immunomodulatory and anti-inflammatory properties (Rehermann and"/>
   <result pre="properties (Rehermann and Bertoletti, 2015). Recently, it was shown that" exact="telbivudine" post="confers endothelial-protective effects on B19V-infected endothelial cells and improves"/>
   <result pre="Clercq, 2018). One of the exceptions is the use of" exact="ribavirin" post="in combination with standard therapy to enhance the current"/>
   <result pre="positively affect HBV treatment. A study on anti-HBV treatment with" exact="ribavirin" post="and tenofovir, compared to tenofovir treatment alone, is currently"/>
   <result pre="study on anti-HBV treatment with ribavirin and tenofovir, compared to" exact="tenofovir" post="treatment alone, is currently in a phase 3 clinical"/>
   <result pre="target multiple stages of the HIV life cycle. Lamivudine and" exact="tenofovir" post="are among the most important drugs used in combination"/>
   <result pre="24 small-molecule combinations most frequently utilized as drug components, anti-HIV" exact="lamivudine" post="occurred 15 times, while tenofovir disoproxil occurred 9 times."/>
   <result pre="utilized as drug components, anti-HIV lamivudine occurred 15 times, while" exact="tenofovir" post="disoproxil occurred 9 times. Lamivudine and tenofovir have been"/>
   <result pre="15 times, while tenofovir disoproxil occurred 9 times. Lamivudine and" exact="tenofovir" post="have been combined with other NRTIs (e.g., abacavir, emtricitabine,"/>
   <result pre="Sciences, 2001 (tenofovir disoproxil fumarate)Truvada, Gilead Sciences, 2004 (emtricitabine +" exact="tenofovir" post="disoproxil fumarate)Atripla, Gilead Sciences, Bristol-Myers Squibb, 2006 (emtricitabine +"/>
   <result pre="tenofovir disoproxil fumarate)Atripla, Gilead Sciences, Bristol-Myers Squibb, 2006 (emtricitabine +" exact="efavirenz" post="+ tenofovir disoproxil fumarate)Complera, Gilead Sciences, 2011 (emtricitabine +"/>
   <result pre="fumarate)Atripla, Gilead Sciences, Bristol-Myers Squibb, 2006 (emtricitabine + efavirenz +" exact="tenofovir" post="disoproxil fumarate)Complera, Gilead Sciences, 2011 (emtricitabine + rilpivirine +"/>
   <result pre="efavirenz + tenofovir disoproxil fumarate)Complera, Gilead Sciences, 2011 (emtricitabine +" exact="rilpivirine" post="+ tenofovir disoproxil fumarate)Stribild, Gilead Sciences, 2012 (elvitegravir +"/>
   <result pre="tenofovir disoproxil fumarate)Complera, Gilead Sciences, 2011 (emtricitabine + rilpivirine +" exact="tenofovir" post="disoproxil fumarate)Stribild, Gilead Sciences, 2012 (elvitegravir + cobicistat +"/>
   <result pre="rilpivirine + tenofovir disoproxil fumarate)Stribild, Gilead Sciences, 2012 (elvitegravir +" exact="cobicistat" post="+ emtricitabine + tenofovir disoproxil fumarate)Delstrigo, Merck, 2018 (doravirine"/>
   <result pre="tenofovir disoproxil fumarate)Stribild, Gilead Sciences, 2012 (elvitegravir + cobicistat +" exact="emtricitabine" post="+ tenofovir disoproxil fumarate)Delstrigo, Merck, 2018 (doravirine + lamivudine"/>
   <result pre="fumarate)Stribild, Gilead Sciences, 2012 (elvitegravir + cobicistat + emtricitabine +" exact="tenofovir" post="disoproxil fumarate)Delstrigo, Merck, 2018 (doravirine + lamivudine +tenofovir disoproxil"/>
   <result pre="+ emtricitabine + tenofovir disoproxil fumarate)Delstrigo, Merck, 2018 (doravirine +" exact="lamivudine" post="+tenofovir disoproxil fumarate)Cimduo, Mylan Pharmaceuticals, 2018 (lamivudine + tenofovir"/>
   <result pre="+ lamivudine +tenofovir disoproxil fumarate)Cimduo, Mylan Pharmaceuticals, 2018 (lamivudine +" exact="tenofovir" post="disoproxil fumarate)Symfi Lo, Mylan Pharmaceuticals, 2018 (efavirenz + lamivudine"/>
   <result pre="+ tenofovir disoproxil fumarate)Symfi Lo, Mylan Pharmaceuticals, 2018 (efavirenz +" exact="lamivudine" post="+ tenofovir disoproxil fumarate) Tenofovir alafenamide fumarate (TAF) Vemlidy,"/>
   <result pre="disoproxil fumarate)Symfi Lo, Mylan Pharmaceuticals, 2018 (efavirenz + lamivudine +" exact="tenofovir" post="disoproxil fumarate) Tenofovir alafenamide fumarate (TAF) Vemlidy, Gilead, 2016"/>
   <result pre="(TAF) Vemlidy, Gilead, 2016 Genvoya, Gilead Sciences 2015 (elvitegravir +" exact="cobicistat" post="+ emtricitabine, + tenofovir alafenamide)Descovy, Gilead Sciences, 2016 (emtricitabine"/>
   <result pre="Genvoya, Gilead Sciences 2015 (elvitegravir + cobicistat + emtricitabine, +" exact="tenofovir" post="alafenamide)Descovy, Gilead Sciences, 2016 (emtricitabine + tenofovir alafenamide)Odefsey, Gilead"/>
   <result pre="+ emtricitabine, + tenofovir alafenamide)Descovy, Gilead Sciences, 2016 (emtricitabine +" exact="tenofovir" post="alafenamide)Odefsey, Gilead Sciences, 2016 (emtricitabine + rilpivirine + tenofovir"/>
   <result pre="2016 (emtricitabine + tenofovir alafenamide)Odefsey, Gilead Sciences, 2016 (emtricitabine +" exact="rilpivirine" post="+ tenofovir alafenamide)Symtuza, Janssen Therapeutics, 2018 (darunavir + cobicistat"/>
   <result pre="+ tenofovir alafenamide)Odefsey, Gilead Sciences, 2016 (emtricitabine + rilpivirine +" exact="tenofovir" post="alafenamide)Symtuza, Janssen Therapeutics, 2018 (darunavir + cobicistat + emtricitabine"/>
   <result pre="+ rilpivirine + tenofovir alafenamide)Symtuza, Janssen Therapeutics, 2018 (darunavir +" exact="cobicistat" post="+ emtricitabine + tenofovir alafenamide)Biktarvy, Gilead Sciences, 2018 (bictegravir"/>
   <result pre="+ tenofovir alafenamide)Symtuza, Janssen Therapeutics, 2018 (darunavir + cobicistat +" exact="emtricitabine" post="+ tenofovir alafenamide)Biktarvy, Gilead Sciences, 2018 (bictegravir + emtricitabine"/>
   <result pre="alafenamide)Symtuza, Janssen Therapeutics, 2018 (darunavir + cobicistat + emtricitabine +" exact="tenofovir" post="alafenamide)Biktarvy, Gilead Sciences, 2018 (bictegravir + emtricitabine + tenofovir"/>
   <result pre="+ emtricitabine + tenofovir alafenamide)Biktarvy, Gilead Sciences, 2018 (bictegravir +" exact="emtricitabine" post="+ tenofovir alafenamide) Lamivudine (3TC) Epivir, Glaxo Wellcome, 1998"/>
   <result pre="+ tenofovir alafenamide)Biktarvy, Gilead Sciences, 2018 (bictegravir + emtricitabine +" exact="tenofovir" post="alafenamide) Lamivudine (3TC) Epivir, Glaxo Wellcome, 1998 Combivir, ViiV"/>
   <result pre="Healthcare, 2000 (lamivudine + zidovudine)Trizivir, ViiV Healthcare, 2000 (abacavir +" exact="lamivudine" post="+ zidovudine)Epzicom, ViiV Healthcare, 2004 (abacavir + lamivudine)Triumeq, ViiV"/>
   <result pre="Healthcare, 2004 (abacavir + lamivudine)Triumeq, ViiV HealthCare, 2014 (abacavir +" exact="dolutegravir" post="+ lamivudine)Dutrebis, Merck, 2015 (lamivudine + raltegravir)Delstrigo, Merck, 2018"/>
   <result pre="lamivudine)Dutrebis, Merck, 2015 (lamivudine + raltegravir)Delstrigo, Merck, 2018 (doravirine +" exact="lamivudine" post="+tenofovir disoproxil fumarate)Cimduo, Mylan Pharmaceuticals, 2018 (lamivudine + tenofovir"/>
   <result pre="+ lamivudine +tenofovir disoproxil fumarate)Cimduo, Mylan Pharmaceuticals, 2018 (lamivudine +" exact="tenofovir" post="disoproxil fumarate)Symfi Lo, Mylan Pharmaceuticals, 2018 (efavirenz + lamivudine"/>
   <result pre="+ tenofovir disoproxil fumarate)Symfi Lo, Mylan Pharmaceuticals, 2018 (efavirenz +" exact="lamivudine" post="+ tenofovir disoproxil fumarate)Dovato, ViiV Healthcare, 2019 (dolutegravir +"/>
   <result pre="disoproxil fumarate)Symfi Lo, Mylan Pharmaceuticals, 2018 (efavirenz + lamivudine +" exact="tenofovir" post="disoproxil fumarate)Dovato, ViiV Healthcare, 2019 (dolutegravir + lamivudine) Fig."/>
   <result pre="Structures of nucleos(t)ide-based and non-nucleoside drugs used in combination with" exact="tenofovir" post="and lamivudine for the treatment of HIV infections. Abbreviations:"/>
   <result pre="nucleos(t)ide-based and non-nucleoside drugs used in combination with tenofovir and" exact="lamivudine" post="for the treatment of HIV infections. Abbreviations: NRTIs -"/>
   <result pre="One of the recently approved anti-HIV combinations, Biktarvy (bictegravir +" exact="emtricitabine" post="+ tenofovir alafenamide), is currently under phase 3 and"/>
   <result pre="the recently approved anti-HIV combinations, Biktarvy (bictegravir + emtricitabine +" exact="tenofovir" post="alafenamide), is currently under phase 3 and 4 clinical"/>
   <result pre="development of anti-HCV drugs. Treatments with pegylated interferon (PEG-IFN) and" exact="ribavirin" post="for HCV eradication have been replaced by the second"/>
   <result pre="the need for co-administration of INF. The high potency of" exact="sofosbuvir" post="is attributable, in part, to the first 5′-phosphate group,"/>
   <result pre="ZIKV RNA polymerases have very similar active sites, confirming that" exact="sofosbuvir" post="could also act on ZIKV-infected cells. It was also"/>
   <result pre="was also demonstrated via cellular assays and animal models that" exact="sofosbuvir" post="inhibits the replication of other flaviviruses, such as dengue"/>
   <result pre="bioavailability of some of the anti-herpesvirus drugs, such as acyclovir," exact="penciclovir" post="or ganciclovir, an amino acid esterification strategy is applied"/>
   <result pre="esterification strategy is applied to obtain compounds such as valaciclovir," exact="famciclovir" post="and valganciclovir, respectively. These &quot;prodrugs�? are rapidly converted into"/>
   <result pre="associated with its systemic use. The mechanism of action of" exact="idoxuridine" post="is not exactly defined, but the triphosphate inhibits viral"/>
   <result pre="both viral and cellular DNA. Currently, in the United States," exact="idoxuridine" post="is approved for only topical treatment of HSV keratitis,"/>
   <result pre="for only topical treatment of HSV keratitis, but in Europe," exact="idoxuridine" post="in DMSO is available for the treatment of herpes"/>
   <result pre="et al., 2010). The results of a comparison of brivudine," exact="famciclovir" post="and valaciclovir treatment in immunocompetent adult patients with herpes"/>
   <result pre="2010). The results of a comparison of brivudine, famciclovir and" exact="valaciclovir" post="treatment in immunocompetent adult patients with herpes zoster indicate"/>
   <result pre="of cancer cell lines. Compared to parent nucleoside, such as" exact="idoxuridine" post="or brivudine, which displayed only weak to moderate activity,"/>
   <result pre="in therapy for HSV-induced epithelial keratitis. After its conversion to" exact="trifluridine" post="monophosphate, it inhibits thymidylate synthetase, which is elevated in"/>
   <result pre="respect to thymidine triphosphate (Aoki, 2015). Trifluridine in combination with" exact="tipiracil" post="(Lonsurf) has been approved in Japan, the United States,"/>
   <result pre="colorectal cancer who were previously subjected to chemotherapy involving fluoropyrimidine," exact="oxaliplatin" post="and irinotecan (Burness and Duggan, 2016; Matsuoka et al.,"/>
   <result pre="who were previously subjected to chemotherapy involving fluoropyrimidine, oxaliplatin and" exact="irinotecan" post="(Burness and Duggan, 2016; Matsuoka et al., 2018). Phase"/>
   <result pre="tested as an antibacterial agent. Specifically, it was found that" exact="trifluridine" post="strongly inhibits Mycoplasma pneumoniae growth in vitro (Sun and"/>
   <result pre="acyclic guanosine analogues, namely, acyclovir, ganciclovir, valaciclovir, valganciclovir, penciclovir, and" exact="famciclovir" post="(Fig. 4). First, acyclovir (ACV, [9-(2-hydroxyethoxy)methyl)guanine]) was originally designed"/>
   <result pre="acyclovir (ACV, [9-(2-hydroxyethoxy)methyl)guanine]) was originally designed as an inhibitor of" exact="adenosine" post="deaminases, but in 1977, it was discovered to be"/>
   <result pre="specific enzymes (Weller et al., 1993). The oral bioavailability of" exact="valaciclovir" post="is much higher than that of acyclovir, reaching almost"/>
   <result pre="than that of acyclovir, reaching almost 50%. In clinical trials," exact="valaciclovir" post="has a similar antiviral activity and safety profile as"/>
   <result pre="the replicative function of the viral DNA polymerase. Unlike acyclovir," exact="penciclovir" post="is not considered a DNA chain terminator due to"/>
   <result pre="acyclic part of PCV, which allows DNA chain elongation. Incorporated" exact="penciclovir" post="probably distorts the DNA conformation and then induces the"/>
   <result pre="higher intracellular concentration compensate for the lower antiviral effect. Phosphorylated" exact="penciclovir" post="concentrations can be as much as 200-fold higher than"/>
   <result pre="acyclovir (Littler and Zhou, 2007; Kimberlin, 2018). The bioavailability of" exact="penciclovir" post="upon oral administration is poor, at approximately 5%; therefore,"/>
   <result pre="oral administration is poor, at approximately 5%; therefore, its prodrug" exact="famciclovir" post="(FCV, 6-deoxypenciclovir diacetate) was designed and approved for clinical"/>
   <result pre="mouse models have shown that the main advantage in using" exact="famciclovir" post="over using other drugs is its ability to prevent"/>
   <result pre="acyclic chain. Due to its highly efficient action against CMV," exact="ganciclovir" post="has been approved for use in the treatment of"/>
   <result pre="after oral administration (Jabs et al., 1986). For this reason," exact="ganciclovir" post="prodrugs have been explored. Valganciclovir (VGCV, 9-[(2-hydroxy-1-valyloxymethyl)ethoxymethyl]guanine), which was"/>
   <result pre="(over 60%). The addition of a valyl ester group to" exact="ganciclovir" post="makes it a good substrate of the two peptide"/>
   <result pre="its absorption. The ester linkage between the valyl group and" exact="ganciclovir" post="is easily hydrolysed by intestinal esterase and hepatic esterase"/>
   <result pre="et al., 2000). Vidarabine (VDR, 9-β-D-arabinofuranosyladenine) is an analogue of" exact="adenosine" post="isolated from Streptomyces antibioticus. Vidarabine, unlike previously discussed drugs,"/>
   <result pre="to generate an active metabolite. When phosphorylated by cellular enzymes," exact="vidarabine" post="is in the active triphosphate form. The lack of"/>
   <result pre="may also contribute to the antiviral and toxic effects of" exact="vidarabine" post="(Aoki, 2015; Theobald, 2016). Vidarabine was initially used as"/>
   <result pre="acyclovir-resistant herpesviruses. Due to its relative insolubility in aqueous media," exact="vidarabine" post="is mainly administered topically (Littler and Zhou, 2007). A"/>
   <result pre="Zhou, 2007). A few years ago, it was proposed that" exact="vidarabine" post="could be applied as a potent and selective inhibitor"/>
   <result pre="methylenecyclopropane nucleoside analogue structurally related to drugs such as acyclovir," exact="ganciclovir" post="and penciclovir. In vitro studies demonstrated its activity against"/>
   <result pre="tested in a phase 2 clinical trial in comparison with" exact="valaciclovir" post="for herpes zoster (NCT00900783) and in a phase 3"/>
   <result pre="and in a phase 3 clinical trial in comparison with" exact="valaciclovir" post="for the prevention of post-herpetic neuralgia (NCT02412917). Brincidofovir (CMX001),"/>
   <result pre="nelarabine, approved in 2005) and pyrimidine analogues (first approved in" exact="cytarabine" post="in 1969, gemcitabine in 1996, azacytidine in 2004, decitabine"/>
   <result pre="2005) and pyrimidine analogues (first approved in cytarabine in 1969," exact="gemcitabine" post="in 1996, azacytidine in 2004, decitabine in 2006, and"/>
   <result pre="in cytarabine in 1969, gemcitabine in 1996, azacytidine in 2004," exact="decitabine" post="in 2006, and floxuridine in 1970), which have had"/>
   <result pre="gemcitabine in 1996, azacytidine in 2004, decitabine in 2006, and" exact="floxuridine" post="in 1970), which have had important roles in several"/>
   <result pre="(Ianevski et al., 2018, 2019). Among them, the cytidine analogue" exact="gemcitabine" post="was reported to be 6th on the list of"/>
   <result pre="2019). Examples of such drugs include gemcitabine, zidovudine, 5-fluorouracil, floxuridine," exact="idoxuridine" post="and thiopurines. The application limitations of some nucleoside analogues"/>
   <result pre="replicating DNA (Cerqueira et al., 2007). Gemzar in combination with" exact="cisplatin" post="was approved in 1998 for the treatment of locally"/>
   <result pre="metastatic non-small cell lung cancer, and Gemzar in combination with" exact="paclitaxel" post="was approved as the first-line therapy for women battling"/>
   <result pre="cancer (at least 6 months after completion of platinum-based therapy)," exact="gemcitabine" post="is used in combination with carboplatin. Another study showed"/>
   <result pre="in combination with carboplatin. Another study showed that co-treatment with" exact="gemcitabine" post="and zidovudine re-sensitized gemcitabine-resistant pancreatic cancer by inhibiting the"/>
   <result pre="with carboplatin. Another study showed that co-treatment with gemcitabine and" exact="zidovudine" post="re-sensitized gemcitabine-resistant pancreatic cancer by inhibiting the key signalling"/>
   <result pre="phase 2 clinical trials have shown that combining brivudine with" exact="gemcitabine" post="or cisplatin enhanced their efficacy as a pancreatic cancer"/>
   <result pre="clinical trials have shown that combining brivudine with gemcitabine or" exact="cisplatin" post="enhanced their efficacy as a pancreatic cancer therapy (Heinrich"/>
   <result pre="been approved. Recently, experimental data on the antiviral activity of" exact="gemcitabine" post="have been widely reported (Shin et al., 2018; Ianevski"/>
   <result pre="et al., 2019). The broad range of viruses against which" exact="gemcitabine" post="has shown activity includes HIV-1 (Rawson et al., 2013;"/>
   <result pre="and FLUAV (Denisova et al., 2012). The synergistic effect of" exact="gemcitabine" post="combined with low doses of other nucleoside analogues was"/>
   <result pre="analogues was also reported. It is applied in combination with" exact="ribavirin" post="for the treatment of enteroviruses or with decitabine for"/>
   <result pre="combination with ribavirin for the treatment of enteroviruses or with" exact="decitabine" post="for the treatment of HIV (Kang et al., 2015;"/>
   <result pre="et al., 2015; Clouser et al., 2010). In most cases," exact="gemcitabine" post="inhibits viruses at low, non-cytotoxic concentrations (Denisova et al.,"/>
   <result pre="al., 2012; Kuivanen et al., 2017). Depending on the virus," exact="gemcitabine" post="was shown to be an inhibitor of viral replication,"/>
   <result pre="viral replication, proliferation, RNA and protein synthesis, or production. The" exact="gemcitabine" post="antiviral effect on enteroviruses was proposed to be based"/>
   <result pre="cellular DNA or RNA synthesis. It is also possible that" exact="gemcitabine" post="can block the RNA polymerase by binding to the"/>
   <result pre="nucleoside available (Song et al., 2017). As a cytidine analogue," exact="gemcitabine" post="was reported to inhibit the salvage pathway of the"/>
   <result pre="the salvage pathway of the pyrimidine biosynthesis. Additionally, treatment with" exact="gemcitabine" post="activates the expression of several IFN-stimulated genes (including CXCL10,"/>
   <result pre="phenomenon could in turn be overcome by the combination of" exact="gemcitabine" post="and gentamicin, which showed synergistic activity and reduced the"/>
   <result pre="silenced (Wolff et al., 2017). Experimental studies have shown that" exact="azacitidine" post="is a potent, broad-spectrum antiviral agent. The range of"/>
   <result pre="rapidly dividing cells by disrupting DNA synthesis. Similar to azacytidine," exact="decitabine" post="also induces immune responses and sensitizes tumours to checkpoint"/>
   <result pre="Additionally, it was shown that in muscle-invasive bladder cancer cells," exact="decitabine" post="treatment (at low non-cytotoxic doses) restored NOTCH1 expression and"/>
   <result pre="CK5 differentiation (Ramakrishnan et al., 2017). The antiviral activity of" exact="decitabine" post="has been shown mostly in HIV treatment. Similar to"/>
   <result pre="described synergistic effect of azacytidine with resveratrol, the combination of" exact="decitabine" post="and resveratrol significantly reduced the levels of HIV-1 reverse"/>
   <result pre="et al., 2016b). Another study indicated that the combination of" exact="gemcitabine" post="and decitabine at concentrations much lower than those used"/>
   <result pre="2016b). Another study indicated that the combination of gemcitabine and" exact="decitabine" post="at concentrations much lower than those used in cancer"/>
   <result pre="et al., 2014). Further study on the anti-HIV-1 activity of" exact="clofarabine" post="revealed its dual inhibitory function in virus replication. It"/>
   <result pre="revealed through an integrated network analysisbioRxiv 1–232019 Bullard-FeibelmanK.M.GoveroJ.ZhuZ.SalazarV.VeselinovicM.DiamondM.S.GeissB.J.The FDA-approved drug" exact="sofosbuvir" post="inhibits Zika virus infectionAntivir. Res.137201713414010.1016/j.antiviral.2016.11.02327902933 BurnessC.B.DugganS.T.Trifluridine/tipiracil: a review in"/>
   <result pre="beyondAntivir. Res.1552018768810.1016/j.antiviral.2018.05.00529758235 ClouserC.L.HoltzC.M.MullettM.CrankshawD.L.BriggsJ.E.O'SullivanM.G.PattersonS.E.ManskyL.M.Activity of a novel combined antiretroviral therapy of" exact="gemcitabine" post="and decitabine in a mouse model for HIV-1Antimicrob. Agents"/>
   <result pre="ClouserC.L.HoltzC.M.MullettM.CrankshawD.L.BriggsJ.E.O'SullivanM.G.PattersonS.E.ManskyL.M.Activity of a novel combined antiretroviral therapy of gemcitabine and" exact="decitabine" post="in a mouse model for HIV-1Antimicrob. Agents Chemother.5620121942194810.1128/aac.06161-1122271861 ClouserC.L.PattersonS.E.ManskyL.M.Exploiting"/>
   <result pre="over the past 50 yearsClin. Microbiol. Rev.29201669574710.1128/CMR.00102-15Address27281742 De ClercqE.Role of" exact="tenofovir" post="alafenamide (TAF) in the treatment and prophylaxis of HIV"/>
   <result pre="zosterBiochem. Pharmacol.6820042301231510.1016/j.bcp.2004.07.03915548377 De FreitasC.S.HigaL.M.SacramentoC.Q.FerreiraA.C.ReisP.A.DelvecchioR.MonteiroF.L.Barbosa-LimaG.James WestgarthH.VieiraY.R.MattosM.RochaN.HoelzL.V.B.LemeR.P.P.BastosM.M.RodriguesG.O.L.LopesC.E.M.Queiroz-JuniorC.M.LimaC.X.CostaV.V.TeixeiraM.M.BozzaF.A.BozzaP.T.BoechatN.TanuriA.SouzaT.M.L.Yellow fever virus is susceptible to" exact="sofosbuvir" post="both in vitro and in vivoPLoS Neglected Trop. Dis.132019e000707210.1371/journal.pntd.0007072"/>
   <result pre="and in vivoPLoS Neglected Trop. Dis.132019e000707210.1371/journal.pntd.0007072 DenisovaO.V.KakkolaL.FengL.StenmanJ.NagarajA.LampeJ.YadavB.AittokallioT.KaukinenP.AholaT.KuivanenS.VapalahtiO.KanteleA.TynellJ.JulkunenI.Kallio-KokkoH.PaavilainenH.HukkanenV.ElliottR.M.De BrabanderJ.K.SaelensX.KainovD.E.Obatoclax, saliphenylhalamide, and" exact="gemcitabine" post="inhibit influenza A virus infectionJ. Biol. Chem.2872012353243533210.1074/jbc.M112.39214222910914 DiamantopoulosP.T.MichaelM.BenopoulouO.BazanisE.TzeletasG.MeletisJ.VayopoulosG.ViniouN.A.Antiretroviral activity"/>
   <result pre="Gouveia PedrosaC.SouzaL.R.Q.LoiolaE.C.TrindadeP.VieiraY.R.Barbosa-LimaG.de Castro Faria NetoH.C.BoechatN.RehenS.K.BrüningK.BozzaF.A.BozzaP.T.SouzaT.M.L.Beyond members of the Flaviviridae family," exact="sofosbuvir" post="also inhibits chikungunya virus replicationAntimicrob. Agents Chemother.63201910.1128/AAC.01389-18e01389-18 FlorescuD.F.PergamS.A.NeelyM.N.QiuF.JohnstonC.WayS.S.SandeJ.LewinsohnD.A.Guzman-CottrillJ.A.GrahamM.L.PapanicolaouG.KurtzbergJ.RigdonJ.PainterW.Mommeja-MarinH.LanierR.AndersonM.van der"/>
   <result pre="Res. Clin. Oncol.13720111349136110.1007/s00432-011-1005-121833720 HertelL.W.BoderG.B.KroinJ.S.RinzelS.M.PooreG. aToddG.C.GrindeyG.B.Evaluation of the antitumor activity of" exact="gemcitabine" post="(2 ′ , 2 ′ evaluation of the antitumor"/>
   <result pre="and in a mouse modelAntivir. Res.1372017142210.1016/j.antiviral.2016.11.00327838352 KaminskasE.FarrellA.T.WangY.-ChSridharaR.PazdurR.FDA drug approval summary:" exact="azacitidine" post="(5-azacytidine, Vidaza) for injectable suspensionThe Oncologist10200517618210.1634/theoncologist.10-3-17615793220 KangH.KimC.KimD.E.SongJ.H.ChoiM.ChoiK.KangM.LeeK.KimH.S.ShinJ.S.KimJ.HanS.B.LeeM.Y.LeeS.U.LeeC.K.KimM.KoH.J.Van KuppeveldF.J.M.ChoS.Synergistic antiviral"/>
   <result pre="Vidaza) for injectable suspensionThe Oncologist10200517618210.1634/theoncologist.10-3-17615793220 KangH.KimC.KimD.E.SongJ.H.ChoiM.ChoiK.KangM.LeeK.KimH.S.ShinJ.S.KimJ.HanS.B.LeeM.Y.LeeS.U.LeeC.K.KimM.KoH.J.Van KuppeveldF.J.M.ChoS.Synergistic antiviral activity of" exact="gemcitabine" post="and ribavirin against enterovirusesAntivir. Res.124201511010.1016/j.antiviral.2015.10.01126526589 KimberlinD.W.Antiviral Agents. Principles and"/>
   <result pre="injectable suspensionThe Oncologist10200517618210.1634/theoncologist.10-3-17615793220 KangH.KimC.KimD.E.SongJ.H.ChoiM.ChoiK.KangM.LeeK.KimH.S.ShinJ.S.KimJ.HanS.B.LeeM.Y.LeeS.U.LeeC.K.KimM.KoH.J.Van KuppeveldF.J.M.ChoS.Synergistic antiviral activity of gemcitabine and" exact="ribavirin" post="against enterovirusesAntivir. Res.124201511010.1016/j.antiviral.2015.10.01126526589 KimberlinD.W.Antiviral Agents. Principles and Practice of"/>
   <result pre="Practice of Pediatric Infectious DiseasesFifth. ed2018 KuivanenS.BespalovM.M.NandaniaJ.IanevskiA.VelagapudiV.De BrabanderJ.K.KainovD.E.VapalahtiO.Obatoclax, saliphenylhalamide and" exact="gemcitabine" post="inhibit Zika virus infection in vitro and differentially affect"/>
   <result pre="NambaT.KodamaR.MoritomoS.HoshinoT.MizushimaT.Zidovudine, an anti-viral drug, resensitizes gemcitabine-resistant pancreatic cancer cells to" exact="gemcitabine" post="by inhibition of the Akt-GSK3β-Snail pathwayCell Death Dis.6201511110.1038/cddis.2015.172 NikkeisA.F.PiérardG.E.Recognition"/>
   <result pre="hepatitis C virusJ. Med. Chem.5320107202721810.1021/jm100863x20845908 SongJ.H.KimS.R.HeoE.Y.LeeJ.Y.KimD. eunChoS.ChangS.Y.YoonB. IlSeongJ.KoH.J.Antiviral activity of" exact="gemcitabine" post="against human rhinovirus in vitro and in vivoAntivir. Res.145201761310.1016/j.antiviral.2017.07.00328705625"/>
   <result pre="inhibitors azacytidine and decitabineInt. J. Cancer123200881310.1002/ijc.2360718425818 SugawaraM.HuangW.FeiY.J.LeibachF.H.GanapathyV.GanapathyM.E.Transport of valganciclovir, a" exact="ganciclovir" post="prodrug, via peptide transporters PEPT1 and PEPT2J. Pharm. Sci.89200078178910.1002/(SICI)1520-6017(200006)89:6&amp;lt;781::AID-JPS10&amp;gt;3.0.CO;2-710824137"/>
   <result pre="anticancer and antiviral nucleoside and nucleobase analogsBMC Microbiol.13201318410.1186/1471-2180-13-18423919755 ThackrayA.M.FieldH.J.Famciclovir and" exact="valaciclovir" post="differ in the prevention of herpes simplex virus type"/>
   <result pre="Physiol. Cell Physiol.3052013H1H810.1152/ajpheart.00080.2013 WellerS.BlumM.R.DoucetteM.BurnetteT.CederbergD.M.MirandaP. DeSmileyM.L.Pharmacolunetics of the acvclovir pro- drug" exact="valaciclovir" post="after iscalati and multiple-dose adrninis tration normal volunteersClin. Pharmacol."/>
   <result pre="nucleoside scaffoldAntivir. Res.162201952110.1016/j.antiviral.2018.11.01630529089 ZhangZ.YangE.HuC.ChengH.ChenC.Y.HuangD.WangR.ZhaoY.RongL.VignuzziM.ShenH.ShenL.ChenZ.W.Cell-based high-throughput screening assay identifies 2′,2′- difluoro-2′-deoxycytidine" exact="gemcitabine" post="as a potential antipoliovirus agentACS Infect. Dis.32017455310.1021/acsinfecdis.6b0011627733043"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="4-part\PMC7175558\results\search\drugs\results.xml">
   <result pre="neuraminidase inhibitor (NAI) treatment was defined as any NAI (oseltamivir," exact="zanamivir" post="and peramivir) administered within 48 h of illness onset [15]."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="4-part\PMC7179685\results\search\drugs\results.xml">
   <result pre="(1994). The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and" exact="zidovudine" post="in patients with HIV-1 infection and 200–500 CD4 Cells/mm.JAIDS7139–147."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="4-part\PMC7182252\results\search\drugs\results.xml">
   <result pre="if they are 4 months or longer posttransplant. Chemoprophylaxis with" exact="oseltamivir" post="or zanamivir should also be initiated for 2 weeks"/>
   <result pre="are 4 months or longer posttransplant. Chemoprophylaxis with oseltamivir or" exact="zanamivir" post="should also be initiated for 2 weeks after vaccination"/>
   <result pre="24 months who are profoundly immunocompromised may be considered for" exact="palivizumab" post="prophylaxis. The development of a potent and long-acting RSV"/>
   <result pre="studies, including a pooled analysis, have shown aerosolized or oral" exact="ribavirin" post="is protective against disease progression to lower respiratory tract"/>
   <result pre="In patients with leukemia, multivariate models demonstrated similar effects.33 Oral" exact="ribavirin" post="has been retrospectively evaluated in patients receiving chemotherapy or"/>
   <result pre="patients with RSV lower respiratory tract infection, use of aerosolized" exact="ribavirin" post="was associated with decreased mortality. Oral or IV ribavirin"/>
   <result pre="aerosolized ribavirin was associated with decreased mortality. Oral or IV" exact="ribavirin" post="although not statistically significant as the effect was smaller.11,12"/>
   <result pre="recipients with RSV have little morbidity and mortality even without" exact="ribavirin" post="therapy.35 Current international guidelines recommend aerosolized or systemic (oral"/>
   <result pre="Current international guidelines recommend aerosolized or systemic (oral or IV)" exact="ribavirin" post="with intravenous immunoglogulin (IVIG) in patients with RSV upper"/>
   <result pre="allogeneic HCT patients with lower respiratory tract infection.36 Recommendations for" exact="ribavirin" post="administration for HCT and SOT recipients, and oncology patients"/>
   <result pre="Table 21.1 . Most data and guidance for use of" exact="ribavirin" post="are in HCT and oncology; few studies have clearly"/>
   <result pre="data are in lung transplant when both oral and IV" exact="ribavirin" post="have been used,37 For HCT and oncology patients, high-risk"/>
   <result pre="could be used to further risk-stratify patients. In general, aerosolized" exact="ribavirin" post="is reserved for subjects with virologically confirmed (BAL positive"/>
   <result pre="3 times daily. Aerosol administration results in high levels of" exact="ribavirin" post="in the secretions, with levels exceeding 1000 μM and"/>
   <result pre="μM and little systemic absorption. The potential environmental release of" exact="ribavirin" post="has caused concern in hospital personnel because of the"/>
   <result pre="concern in hospital personnel because of the potential teratogenicity of" exact="ribavirin" post="and thus exposure is contraindicated in pregnant women because"/>
   <result pre="in pregnant women because of its teratogenic potential. Administration of" exact="ribavirin" post="via a ventilator, using a high-dose, short-duration method of"/>
   <result pre="a vacuum-exhausted treatment hood, results in minimal or no detectable" exact="ribavirin" post="in the rooms of treated children. TABLE 21.1 Prevention"/>
   <result pre="Oncology: Ribavirin for high-risk situationsa,b,c •SOT: limited data; consider oral" exact="ribavirin" post="in lung transplant •Isolation •Low-risk situations in HCT and"/>
   <result pre="oral ribavirinb •High-risk situations in HCT and oncology: consider aerosolized" exact="ribavirin" post="initially followed by oralb,c •SOT: consider oral or aerosolized"/>
   <result pre="ribavirin initially followed by oralb,c •SOT: consider oral or aerosolized" exact="ribavirin" post="in lung transplant •Supportive care Influenza A/B •Infection control"/>
   <result pre="anti−B-cell antibodies in the past 6 months •Isolation •Oseltamivir or" exact="zanamivir" post="•Isolation •Oseltamivir or zanamivir •Isolation •Oseltamivir or zanamivir •Consider"/>
   <result pre="past 6 months •Isolation •Oseltamivir or zanamivir •Isolation •Oseltamivir or" exact="zanamivir" post="•Isolation •Oseltamivir or zanamivir •Consider combination therapy with baloxavir"/>
   <result pre="•Oseltamivir or zanamivir •Isolation •Oseltamivir or zanamivir •Isolation •Oseltamivir or" exact="zanamivir" post="•Consider combination therapy with baloxavir if ≥ 12 years,"/>
   <result pre="•Consider combination therapy with baloxavir if ≥ 12 years, or" exact="rimantadine" post="(only influenza A) and/or ribavirin •Consider IV peramivir if"/>
   <result pre="if ≥ 12 years, or rimantadine (only influenza A) and/or" exact="ribavirin" post="•Consider IV peramivir if mechanically ventilated •Supportive care PIV"/>
   <result pre="years, or rimantadine (only influenza A) and/or ribavirin •Consider IV" exact="peramivir" post="if mechanically ventilated •Supportive care PIV •Infection control procedures"/>
   <result pre="•Isolation •Consider reduction of steroid dose •Isolation •Supportive care •Consider" exact="ribavirin" post="if mechanically ventilatedb HMPV •Infection control procedures •Isolation •Isolation"/>
   <result pre="HMPV •Infection control procedures •Isolation •Isolation •Isolation •Supportive care •Consider" exact="ribavirin" post="if mechanically ventilatedb HRV •Infection control procedures •Isolation •Isolation"/>
   <result pre="the use of aerosolized ribavirin. bBenefit and dosing of oral" exact="ribavirin" post="not clearly understood. cHigh risk: lymphopenia, smoking history, and"/>
   <result pre="lymphopenia, smoking history, and use of high-dose total-body irradiation. Oral" exact="ribavirin" post="can be considered in patients weighing more than 15kg;"/>
   <result pre="treat RSV disease. The combination of high-titer RSV immunoglobulin and" exact="ribavirin" post="has been associated with therapeutic success in uncontrolled studies"/>
   <result pre="lower respiratory tract infection suggested a beneficial effect of adjunctive" exact="palivizumab" post="or IVIG.38 Larger studies of HCT recipients with RSV"/>
   <result pre="infection were unable to demonstrate improved outcomes with adjunctive palivizumab11,12;" exact="palivizumab" post="is not currently recommended for treatment of RSV infection"/>
   <result pre="of RSV infection in any immunocompromised patients. The duration of" exact="ribavirin" post="therapy in immunocompromised hosts is generally at least 3"/>
   <result pre="oseltamivir, inhaled zanamivir, IV peramivir, and baloxavir. Clinical efficacy with" exact="oseltamivir" post="and inhaled zanamivir has been demonstrated in patients with"/>
   <result pre="IV peramivir, and baloxavir. Clinical efficacy with oseltamivir and inhaled" exact="zanamivir" post="has been demonstrated in patients with leukemia or HCT"/>
   <result pre="in patients with leukemia or HCT recipients.18 Many mutations causing" exact="oseltamivir" post="and peramivir resistance, including the common H275Y mutation in"/>
   <result pre="with leukemia or HCT recipients.18 Many mutations causing oseltamivir and" exact="peramivir" post="resistance, including the common H275Y mutation in A(H1N1)pdm09 influenza,"/>
   <result pre="A(H1N1)pdm09 influenza, do not confer resistance to zanamivir40 and inhaled" exact="zanamivir" post="may be used to treat these strains. IV peramivir"/>
   <result pre="inhaled zanamivir may be used to treat these strains. IV" exact="peramivir" post="used during the 2009 pandemic in severely ill patients"/>
   <result pre="recovery in most patients.41 In a randomized trial comparing IV" exact="peramivir" post="to oral oseltamivir in hospitalized adults, clinical outcomes were"/>
   <result pre="patients.41 In a randomized trial comparing IV peramivir to oral" exact="oseltamivir" post="in hospitalized adults, clinical outcomes were similar.42 The optimal"/>
   <result pre="hospitalized adults, clinical outcomes were similar.42 The optimal duration of" exact="peramivir" post="therapy has not been determined for immunocompromised hosts. Longer"/>
   <result pre="Longer treatment courses (10 days), although not higher doses, with" exact="oseltamivir" post="or zanamivir have been suggested, given the potential for"/>
   <result pre="courses (10 days), although not higher doses, with oseltamivir or" exact="zanamivir" post="have been suggested, given the potential for recurrence and"/>
   <result pre="in immunocompromised patients. Triple-combination antiviral therapy with amantadine, ribavirin, and" exact="oseltamivir" post="has been proposed to treat immunocompromised patients with severe"/>
   <result pre="to oseltamivir. A randomized trial comparing triple-combination antiviral therapy with" exact="oseltamivir" post="alone in high-risk adults demonstrated an effect on viral"/>
   <result pre="of patients with leukemia or HCT recipients with PIV infection," exact="ribavirin" post="had no impact on viral shedding, symptom and hospitalization"/>
   <result pre="infection, or mortality.45 A systematic review evaluated aerosolized or systemic" exact="ribavirin" post="in 10 retrospective studies in this same population and"/>
   <result pre="respiratory tract infection.46 Given lack of evidence of clinical efficacy," exact="ribavirin" post="is not recommended for PIV infections. The impact of"/>
   <result pre="hosts (with and without IVIG). Lack of controlled studies of" exact="ribavirin" post="and the known toxicities of therapy, including hemolytic anemia,"/>
   <result pre="novel influenza therapeutics are under investigation, including the NAIs IV" exact="zanamivir" post="and laninamivir, monoclonal antibodies, viral polymerase inhibitors, and nitazoxanide."/>
   <result pre="organ transplantationAm J Transplant13suppl 4201321221923465014 29.IsonMGSzakalyPShapiraMYKrivanGNistADutkowskiREfficacy and safety of oral" exact="oseltamivir" post="for influenza prophylaxis in transplant recipientsAntivir Ther176201295596422728756 30.RalstonSLLieberthalASMeissnerHCClinical practice"/>
   <result pre="management, and prevention of bronchiolitisPediatrics13452014e147450225349312 31.Reassessment of the indications for" exact="ribavirin" post="therapy in respiratory syncytial virus infectionsAmerican Academy of Pediatrics"/>
   <result pre="syncytial virus infection in patients with leukemiaHaematologica92920071216162317666367 34.FooladFAitkenSLShigleTLOral versus aerosolized" exact="ribavirin" post="for the treatment of respiratory syncytial virus infections in"/>
   <result pre="cell transplantation recipientsClin Infect Dis2018doi: 10.1093/cid/ciy760 35.El-Bietar JNelsonAWallaceGRSV infection without" exact="ribavirin" post="treatment in pediatric hematopoietic stem cell transplantationBone Marrow Transplant511020161382138427183091"/>
   <result pre="virus, parainfluenza virus, metapneumovirus, rhinovirus, and coronavirusClin Infect Dis562201325826623024295 37.BurrowsFSCarlosLMBenzimraMOral" exact="ribavirin" post="for respiratory syncytial virus infection after lung transplantation: efficacy"/>
   <result pre="320131823 41.HernandezJEAdigaRArmstrongRClinical experience in adults and children treated with intravenous" exact="peramivir" post="for 2009 influenza A (H1N1) under an emergency IND"/>
   <result pre="the United StatesClin Infect Dis526201169570621367722 42.IsonMGHuiDSClezyKA clinical trial of intravenous" exact="peramivir" post="compared with oral oseltamivir for the treatment of seasonal"/>
   <result pre="Dis526201169570621367722 42.IsonMGHuiDSClezyKA clinical trial of intravenous peramivir compared with oral" exact="oseltamivir" post="for the treatment of seasonal influenza in hospitalized adultsAntivir"/>
   <result pre="in adults and adolescentsN Engl J Med37910201891392330184455 44.BeigelJHBaoYBeelerJOseltamivir, amantadine, and" exact="ribavirin" post="combination antiviral therapy versus oseltamivir monotherapy for the treatment"/>
   <result pre="J Med37910201891392330184455 44.BeigelJHBaoYBeelerJOseltamivir, amantadine, and ribavirin combination antiviral therapy versus" exact="oseltamivir" post="monotherapy for the treatment of influenza: a multicentre, double-blind,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="4-part\PMC7182600\results\search\drugs\results.xml">
   <result pre="hCK cells were maintained in the presence of 2 µg/mL" exact="puromycin" post="and 10 µg/mL blasticidin in MEM containing 5% NCS.9"/>
   <result pre="were used in this study. Ferrets were anesthetized intramuscularly with" exact="ketamine" post="and xylazine (5�?30 mg and 0.2�?6 mg/kg of body"/>
   <result pre="was used to characterize the susceptibility of B/Tokyo/UT�?AC032/2018 virus to" exact="oseltamivir" post="carboxylate, peramivir, zanamivir, and laninamivir (Table 4). The isolate"/>
   <result pre="from B/Phuket/3073/2013). This isolate also exhibited moderately reduced susceptibility to" exact="oseltamivir" post="carboxylate (eightfold). Table 4 Virus sensitivity to NA inhibitors"/>
   <result pre="this study. We also thank Daiichi Sankyo Inc for providing" exact="oseltamivir" post="carboxylate, peramivir, and laminamivir, Chiharu Kawakami for providing B/Yokohama/5/2004,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="4-part\PMC7183126\results\search\drugs\results.xml">
   <result pre="Protocol HIV-1 integrase resistance associated mutations and the use of" exact="dolutegravir" post="in Sub-Saharan Africa: a systematic review and meta-analysis protocol"/>
   <result pre="settings. This review aims at synthesizing the current knowledge on" exact="dolutegravir" post="use and integrase resistance-associated mutations found before the wide"/>
   <result pre="randomized and non-randomized trials, cohort, and cross-sectional studies published on" exact="dolutegravir" post="use or integrase resistance-associated mutations in Sub-Saharan Africa. Searches"/>
   <result pre="of adults and/or children exposed to integrase inhibitors-based therapies; especially" exact="dolutegravir" post="or raltegravir (which is our intervention of interest as"/>
   <result pre="and/or children exposed to integrase inhibitors-based therapies; especially dolutegravir or" exact="raltegravir" post="(which is our intervention of interest as compared to"/>
   <result pre="inhibitors by contributing to current knowledge on the use of" exact="dolutegravir" post="and/or raltegravir (especially for neonates) in Sub-Saharan Africa. Results"/>
   <result pre="contributing to current knowledge on the use of dolutegravir and/or" exact="raltegravir" post="(especially for neonates) in Sub-Saharan Africa. Results will therefore"/>
   <result pre="host cells. There are currently five drugs in this class;" exact="raltegravir" post="(RAL), elvitegravir (EVG), dolutegravir (DTG), cabotegravir (CAB), bictegravir (BIC)"/>
   <result pre="There are currently five drugs in this class; raltegravir (RAL)," exact="elvitegravir" post="(EVG), dolutegravir (DTG), cabotegravir (CAB), bictegravir (BIC) [1–7]. These"/>
   <result pre="currently five drugs in this class; raltegravir (RAL), elvitegravir (EVG)," exact="dolutegravir" post="(DTG), cabotegravir (CAB), bictegravir (BIC) [1–7]. These INSTIs are"/>
   <result pre="Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and" exact="tenofovir" post="alafenamide from boosted protease inhibitor-based regimens in virologically suppressed"/>
   <result pre="C, Podzamczer D, Tebas P, et al. Bictegravir, emtricitabine, and" exact="tenofovir" post="alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment"/>
   <result pre="al. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and" exact="lamivudine" post="for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind,"/>
   <result pre="Lippincott Williams and Wilkins; 2017. p. 343–350. 8.AkihisaEKawauchi-MikiSMikiSSatoAWakasa-MorimotoCFujiwaraTet al.Effects of" exact="raltegravir" post="or elvitegravir resistance signature mutations on the barrier to"/>
   <result pre="and Wilkins; 2017. p. 343–350. 8.AkihisaEKawauchi-MikiSMikiSSatoAWakasa-MorimotoCFujiwaraTet al.Effects of raltegravir or" exact="elvitegravir" post="resistance signature mutations on the barrier to dolutegravir resistance"/>
   <result pre="raltegravir or elvitegravir resistance signature mutations on the barrier to" exact="dolutegravir" post="resistance in vitroAntimicrob Agents Chemother.20155952596260610.1128/AAC.04844-1425691633 9.GantnerPLeeGQReyDMespledeTPartisaniMCheneauCet al.Dolutegravir reshapes the"/>
   <result pre="reservoirsJ Antimicrob Chemother.20187341045105310.1093/jac/dkx47529244129 10.Wainberg MA, Han Y-S, Mesplède T. Might" exact="dolutegravir" post="be part of a functional cure for HIV? Can"/>
   <result pre="López-Cortés L, et al. Switching to fixed-dose bictegravir, emtricitabine, and" exact="tenofovir" post="alafenamide from dolutegravir plus abacavir and lamivudine in virologically"/>
   <result pre="al. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from" exact="dolutegravir" post="plus abacavir and lamivudine in virologically suppressed adults with"/>
   <result pre="to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus" exact="abacavir" post="and lamivudine in virologically suppressed adults with HIV-1: 48 week"/>
   <result pre="bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and" exact="lamivudine" post="in virologically suppressed adults with HIV-1: 48 week results of"/>
   <result pre="DeJesus E, Stellbrink H-JJ, et al. Coformulated bictegravir, emtricitabine, and" exact="tenofovir" post="alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for"/>
   <result pre="H-JJ, et al. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus" exact="dolutegravir" post="with emtricitabine and tenofovir alafenamide, for initial treatment of"/>
   <result pre="al. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with" exact="emtricitabine" post="and tenofovir alafenamide, for initial treatment of HIV-1 infection"/>
   <result pre="bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and" exact="tenofovir" post="alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="4-part\PMC7183472\results\search\drugs\results.xml">
   <result pre="2017. To avoid animal suffering, bats were initially premedicated with" exact="atropine" post="(0.005 mg/kg; Laboratories ZOO, Bogota, Colombia) and acepromazine (0.11"/>
   <result pre="premedicated with atropine (0.005 mg/kg; Laboratories ZOO, Bogota, Colombia) and" exact="acepromazine" post="(0.11 mg/Kg; Laboratories ZOO, Bogota, Colombia) by intramuscularly route"/>
   <result pre="administration and euthanized by overdose de 0.2 ml of sodium" exact="pentobarbital" post="by intracardiac (Invet, Bogota, Colombia). Brain, heart, lung, liver,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="4-part\PMC7190985\results\search\drugs\results.xml">
   <result pre="FBS and 10 units/mL of penicillin and 100 μg/mL of" exact="streptomycin" post="(penicillin–streptomycin). For all experiments involving viral infection, DMEM containing"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="4-part\PMC7192973\results\search\drugs\results.xml">
   <result pre="threat [[2], [3], [4]]. Vaccination and antiviral drugs such as" exact="oseltamivir" post="are efficient approaches for controlling influenza symptoms, but numerous"/>
   <result pre="overnight at 37 °C with 5% CO2, cells were treated with" exact="dimethyl sulfoxide" post="(DMSO) or two-fold serial dilutions of erucic acid (9.375 nM"/>
   <result pre="with diluted compounds including erucic acid and the positive control" exact="oseltamivir" post="carboxylate (TLC PharmaChem., Inc., Canada) in TPCK-trypsin (1.5 μg/mL) containing"/>
   <result pre="for 7 days) at 2 days prior to viral infection;" exact="oseltamivir" post="phosphate treatment group, intragastric administration of oseltamivir phosphate (60 mg/kg/d,"/>
   <result pre="to viral infection; oseltamivir phosphate treatment group, intragastric administration of" exact="oseltamivir" post="phosphate (60 mg/kg/d, for 7 days) at 2 days prior"/>
   <result pre="For viral infection, mice were anesthetized by inhalation of 5%" exact="isoflurane" post="and inoculated intranasally with 5 LD50 of mouse-adapted A/FM/1/47(H1N1)"/>
   <result pre="drugs are used clinically in influenza therapy; however, even early" exact="oseltamivir" post="treatment does not improve the outcome of critically ill"/>
   <result pre="inflammatory and wnt-mediated signaling in miceJ. Virol.9020152240225326656717 7KumarA.Early versus late" exact="oseltamivir" post="treatment in severely ill patients with 2009 pandemic influenza"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="4-part\PMC7198842\results\search\drugs\results.xml">
   <result pre="are resident macrophages, CCL2, IL-6, RANKL (187), osteoprotegerin, TRAF6, NFATc1," exact="calcitonin" post="receptors, cathepsin K, and β3 integrin (184, 188); degradation"/>
   <result pre="regulates the expression of genes involved in osteoclast differentiation e.g.," exact="calcitonin" post="receptor, cathepsin K, and β3 integrin. Secretion of IL-1"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="4-part\PMC7200043\results\search\drugs\results.xml">
   <result pre="Prospective observational study on the pharmacokinetic properties of the Irrua" exact="ribavirin" post="regimen used in routine clinical practice in patients with"/>
   <result pre="care and the broad-spectrum antiviral agent ribavirin. However, evidence for" exact="ribavirin" post="efficacy in patients with LF is poor and pharmacokinetic"/>
   <result pre="not available. Irrua Specialist Teaching Hospital (ISTH) developed an intravenous" exact="ribavirin" post="regimen different to the WHO recommendation. Apart from a"/>
   <result pre="this study is to characterise the PK of the Irrua" exact="ribavirin" post="regimen. Methods and analysis This prospective, observational clinical study"/>
   <result pre="observational clinical study will assess PK properties of the Irrua" exact="ribavirin" post="regimen on routinely ribavirin-treated patients with LF at ISTH,"/>
   <result pre="The primary objective is to describe classical PK parameters for" exact="ribavirin" post="(maximum plasma drug concentration, time to maximum plasma drug"/>
   <result pre="doses on day 1, day 4 and day 10 of" exact="ribavirin" post="treatment. Ribavirin plasma concentrations will be determined using liquid"/>
   <result pre="and limitations of this study Pharmacological analysis of the Irrua" exact="ribavirin" post="regimen will provide pharmacokinetic data on intravenous ribavirin treatment,"/>
   <result pre="the Irrua ribavirin regimen will provide pharmacokinetic data on intravenous" exact="ribavirin" post="treatment, the current standard treatment in patients with Lassa"/>
   <result pre="than in untreated controls.16 17 The mode of action of" exact="ribavirin" post="against LASV is not clear. Recently, it has been"/>
   <result pre="Recently, it has been shown with other RNA viruses that" exact="ribavirin" post="can be incorporated into the RNA strand leading to"/>
   <result pre="lethal mutagenesis or error catastrophe. Evidence for the currently recommended" exact="ribavirin" post="treatment (30 mg/kg loading dose followed by 15 mg/kg every 6 hours"/>
   <result pre="data exist about the rational for this dose, the achieved" exact="ribavirin" post="blood levels under this dose or the efficacy and"/>
   <result pre="scientific evidence is still largely lacking behind. PK assessments of" exact="ribavirin" post="are only available for different dosing regimens used for"/>
   <result pre="regimens used for hepatitis C.25 The multiple dose half-life of" exact="ribavirin" post="is estimated to be approximately 300 hours (12.5 days), which"/>
   <result pre="with LF in any institution in Nigeria, ISTH developed a" exact="ribavirin" post="regimen different from the WHO recommendation which is here"/>
   <result pre="which is here referred to as ‘Irrua regimen’ or ‘Irrua" exact="ribavirin" post="treatment regimen’.27 Apart from a higher loading dose and"/>
   <result pre="as the study by McCormick et al demonstrated efficacy of" exact="ribavirin" post="in reducing the fatality rate of LF; ribavirin also"/>
   <result pre="efficacy of ribavirin in reducing the fatality rate of LF;" exact="ribavirin" post="also increases survival in in vivo animal models of"/>
   <result pre="experience during the last decade, the standard Irrua regimen of" exact="ribavirin" post="is postulated to be efficacious. Yet it is easier"/>
   <result pre="However, to our knowledge, the PK properties of the Irrua" exact="ribavirin" post="regimen have never been described. It is not known"/>
   <result pre="this prospective observational study we aim to obtain evidence on" exact="ribavirin" post="PKs in patients who receive the Irrua ribavirin regimen"/>
   <result pre="evidence on ribavirin PKs in patients who receive the Irrua" exact="ribavirin" post="regimen as standard of care at ISTH. The Irrua"/>
   <result pre="of care at ISTH. The Irrua regimen entails the following" exact="ribavirin" post="dosages for intravenous use: Start dose (day 1): 100 mg/kg;"/>
   <result pre="for further clinical studies studying the efficacy and safety of" exact="ribavirin" post="and provide the possibility to compare the Irrua regimen"/>
   <result pre="This will serve as basis for further dose optimisation of" exact="ribavirin" post="helping to further ameliorate the management of patients with"/>
   <result pre="LF. Primary research question What are the PK properties of" exact="ribavirin" post="administered as per the Irrua ribavirin treatment regimen to"/>
   <result pre="the PK properties of ribavirin administered as per the Irrua" exact="ribavirin" post="treatment regimen to patients with LF? Study objectives General"/>
   <result pre="of this study is to describe the PK properties of" exact="ribavirin" post="when administered in routine care under the Irrua dosing"/>
   <result pre="Specific objectives Primary objective Describe the classical PK parameters for" exact="ribavirin" post="(maximum plasma drug concentration (Cmax), time to maximum plasma"/>
   <result pre="distribution (Vd)) in patients with LF treated with the Irrua" exact="ribavirin" post="regimen. Secondary objectives Examine the clinical, haematological, biochemical parameters"/>
   <result pre="haematological, biochemical parameters of the patients and correlate them with" exact="ribavirin" post="blood levels. Study the kinetics of LASV loads in"/>
   <result pre="be conducted to assess the PK properties of the Irrua" exact="ribavirin" post="regimen on routinely ribavirin-treated patients with LF at the"/>
   <result pre="consent. Primary end point PK parameters of the routine care" exact="ribavirin" post="regimen at ISTH. Secondary end points Viral kinetics in"/>
   <result pre="points Viral kinetics in patients routinely treated with the Irrua" exact="ribavirin" post="regimen. LASV genome changes under the Irrua ribavirin regimen."/>
   <result pre="the Irrua ribavirin regimen. LASV genome changes under the Irrua" exact="ribavirin" post="regimen. Study site The Lassa Unit of the ISTH"/>
   <result pre="pregnant within the upcoming 3 months. Patients who already received" exact="ribavirin" post="within the last 7 days. Concomitant administration of didanosine"/>
   <result pre="received ribavirin within the last 7 days. Concomitant administration of" exact="didanosine" post="and other contraindicated concomitant medication. Enrolment Recruitment of patients"/>
   <result pre="study participation. Furthermore, children and pregnant women do not receive" exact="ribavirin" post="intravenously but orally and are therefore not eligible for"/>
   <result pre="with different treatments or treatment regimens (eg, the WHO recommended" exact="ribavirin" post="regimen) will be performed. The potential bias in this"/>
   <result pre="contraindicating the collection of blood or premature termination of intravenous" exact="ribavirin" post="administration due to clinical improvement and switch to oral"/>
   <result pre="doses on day 1, day 4 and day 10 of" exact="ribavirin" post="treatment. Additionally, it will be collected during screening before"/>
   <result pre="Clinical Pharmacy, Institute of Pharmacy, University of Hamburg, Germany). There," exact="ribavirin" post="plasma concentrations will be determined using liquid chromatography coupled"/>
   <result pre="with the goal to characterise the typical PK parameters of" exact="ribavirin" post="and PK variability. Linear as well as non-linear compartmental"/>
   <result pre="in PK. In particular, we will analyse the changes in" exact="ribavirin" post="concentration and haemoglobin levels, ALT/GPT and uric acid. These"/>
   <result pre="acid. These are prognostic markers for survival, for metabolism of" exact="ribavirin" post="and for potential side effects and toxicity (eg, haemolysis)."/>
   <result pre="on changes in longitudinal biological parameters as described previously for" exact="ribavirin" post="in patients with HCV.34 PK-PD modelling The PK data"/>
   <result pre="to evaluate the effect (or the lack of effect) of" exact="ribavirin" post="monotherapy on the Lassa viral kinetics. Semi-mechanistic modelling of"/>
   <result pre="StephenELEnhanced treatment of Lassa fever by immune plasma combined with" exact="ribavirin" post="in cynomolgus monkeys. J Infect Dis1984;149:420–7. 10.1093/infdis/149.3.4206715898 18StephenEL, JahrlingPBExperimental"/>
   <result pre="A2001;98:6895–900. 10.1073/pnas.11108559811371613 21CrottyS, MaagD, ArnoldJJ, et al.The broad-spectrum antiviral ribonucleoside" exact="ribavirin" post="is an RNA virus mutagen. Nat Med2000;6:1375–9. 10.1038/8219111100123 22McCormickJB,"/>
   <result pre="Infect Dis2019;87:15–20. 10.1016/j.ijid.2019.07.01531357056 24collab: World Health OrganisationApplication for inclusion of" exact="ribavirin" post="in the WHO model list of essential medicines2006. 25PrestonSL,"/>
   <result pre="medicines2006. 25PrestonSL, DrusanoGL, GlueP, et al.Pharmacokinetics and absolute bioavailability of" exact="ribavirin" post="in healthy volunteers as determined by stable-isotope methodology. Antimicrob"/>
   <result pre="LüdtkeA, et al.Efficacy of Favipiravir alone and in combination with" exact="ribavirin" post="in a lethal, immunocompetent mouse model of Lassa fever."/>
   <result pre="10.1093/infdis/jiv52226531247 29JinR, FosslerMJ, McHutchisonJG, et al.Population pharmacokinetics and pharmacodynamics of" exact="ribavirin" post="in patients with chronic hepatitis C genotype 1 infection."/>
   <result pre="Negl Trop Dis2017;11:e0005389. 10.1371/journal.pntd.000538928231247 32LoregianA, ScarpaMC, PagniS, et al.Measurement of" exact="ribavirin" post="and evaluation of its stability in human plasma by"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="4-part\PMC7203554\results\search\drugs\results.xml">
   <result pre="impaired its attachment and internalization. Nonetheless, inhibition of ASMase by" exact="desipramine" post="did not affect IAV infection. Similarly, virus replication was"/>
   <result pre="glutamax (100X), 1% penicillin-streptomycin (10,000 units penicillin and 10,000 units" exact="streptomycin" post="per ml) and 0.08% gentamicin (50 mg/ml). VIM was"/>
   <result pre="assay as described below. Reagent Preparation A 10 mM of" exact="desipramine" post="(Sigma, D3900) stock, an inhibitor of ASMase (Hurwitz et"/>
   <result pre="a functional inhibitor of ASMase. Dose and time-dependent cytotoxicity of" exact="desipramine" post="on A549 cells were first studied using MTT assay."/>
   <result pre="up to 48 h (Figure 4B). We further verified that" exact="desipramine" post="(25 μM) treatment significantly reduces ASMase activity in A549"/>
   <result pre="4 ASMase is dispensable for IAV infection (A,B) Cytotoxicity of" exact="desipramine" post="(Des) in A549 cells was assessed using the MTT"/>
   <result pre="using the MTT assay. A549 cells were treated with increasing" exact="desipramine" post="concentrations for 24 h (A) or with desipramine at"/>
   <result pre="with increasing desipramine concentrations for 24 h (A) or with" exact="desipramine" post="at 12.5 μM or 25 μM for the indicated"/>
   <result pre="μM for the indicated durations (B). (C) The effect of" exact="desipramine" post="on ASMase activity in A549 cells was determined. A549"/>
   <result pre="to the vehicle-treated cells. A549 cells were either treated with" exact="desipramine" post="for 1 h or left untreated prior to inoculation"/>
   <result pre="ASMase inhibition on IAV propagation. A549 cells were treated with" exact="desipramine" post="for 1 h before inoculation with 1 MOI of"/>
   <result pre="was maintained in the culture media during infection. Treatment with" exact="desipramine" post="at 12.5 and 25 μM did not affect IAV"/>
   <result pre="et al., 2012; Huang et al., 2018), ASMase inhibition using" exact="desipramine" post="did not affect IAV infection. Furthermore, IAV was able"/>
   <result pre="belongs to the group of lysosomotropic weak bases, which includes" exact="amantadine" post="and chloroquine, both known to inhibit IAV (Wang et"/>
   <result pre="al., 2010). A common mechanism underlying the inhibitory effect of" exact="amantadine" post="and chloroquine against IAV is through inhibiting endosomal activation"/>
   <result pre="A common mechanism underlying the inhibitory effect of amantadine and" exact="chloroquine" post="against IAV is through inhibiting endosomal activation and low-pH"/>
   <result pre="(Steinhauer et al., 1991; Di Trani et al., 2007). Besides," exact="amantadine" post="blocks the viral M2 channel and subsequently inhibits the"/>
   <result pre="virus life cycle (Wang et al., 1993). In this study," exact="desipramine" post="had no inhibitory effect against IAV despite being a"/>
   <result pre="is much less potent in neutralizing endosomal vesicles compared to" exact="chloroquine" post="albeit having a higher inhibitory effect against ASMase (Kornhuber"/>
   <result pre="et al., 2011). Therefore, the lack of inhibitory effect by" exact="desipramine" post="against IAV might be both due to its failure"/>
   <result pre="Different pH requirements are associated with divergent inhibitory effects of" exact="chloroquine" post="on human and avian influenza A viruses.Virol. J.4:39. 10.1186/1743-422X-4-3917477867"/>
   <result pre="(MDCK) cells.J. Virol. Methods1117–120. 10.1016/0166-0934(80)90020-87228969 HurwitzR.FerlinzK.SandhoffK. (2009). The tricyclic antidepressant" exact="desipramine" post="causes proteolytic degradation of lysosomal sphingomyelinase in human fibroblasts.Biol."/>
   <result pre="activity of influenza A virus M2 protein: characterization of the" exact="amantadine" post="block.J. Virol.675585–5594. 10.1128/jvi.67.9.5585-5594.19937688826 WengL.HirataY.AraiM.KoharaM.WakitaT.WatashiK.et al. (2010). Sphingomyelin activates hepatitis"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="4-part\PMC7207162\results\search\drugs\results.xml">
   <result pre="AAV vector particles were purified via isopycnic centrifugation through an" exact="iodixanol" post="(Axis�?Shield, Dundee, UK) step gradient and concentrated with Amicon"/>
   <result pre="aiming at a power of 80%. Mice were anesthetized by" exact="isoflurane" post="inhalation, before 50 μl PBS containing 1011 vg of"/>
   <result pre="presenting ≥ 20% weight loss were anesthetized and euthanized by" exact="isoflurane" post="overdosing and lungs were harvested. Lungs of surviving mice"/>
   <result pre="to the experiment. Ferrets were anesthetized by intramuscular injection of" exact="ketamine" post="(100 mg/kg) and medetomidine (0.05 mg/kg), before a total"/>
   <result pre="were anesthetized by intramuscular injection of ketamine (100 mg/kg) and" exact="medetomidine" post="(0.05 mg/kg), before a total of 300 μl PBS"/>
   <result pre="On day 3 post�?infection, animals were anesthetized by injection of" exact="ketamine" post="(100 mg/kg) and medetomidine (0.05 mg/kg), exsanguinated, and nasal"/>
   <result pre="animals were anesthetized by injection of ketamine (100 mg/kg) and" exact="medetomidine" post="(0.05 mg/kg), exsanguinated, and nasal turbinates, trachea and lung"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="4-part\PMC7211204\results\search\drugs\results.xml">
   <result pre="of a murine version of the anti-respiratory syncytial virus antibody" exact="palivizumab" post="using Ad serotype 5 and AAVrh.10 vectors, showing protection"/>
   <result pre="CAR-T field, Mestermann et al. employed the tyrosine kinase inhibitor" exact="dasatinib" post="to suppress T-cell receptor signaling [88]. However, dasatinib has"/>
   <result pre="kinase inhibitor dasatinib to suppress T-cell receptor signaling [88]. However," exact="dasatinib" post="has been shown to be toxic in skeletal muscle"/>
   <result pre="shown to be toxic in skeletal muscle cells [89]. Furthermore," exact="dasatinib" post="does not completely remove CAR-T from circulation, rather it"/>
   <result pre="expression and impact in small animal studies. Advancements such as" exact="hyaluronidase" post="pre-treatment of muscles to transiently facilitate dispersion through the"/>
   <result pre="studies, Yamazaki et al. observed 4-ng/mL expression in mice before" exact="hyaluronidase" post="pre-treatment and as high as &amp;gt; 15 μg/mL following hyaluronidase pre-treatment"/>
   <result pre="mice before hyaluronidase pre-treatment and as high as &amp;gt; 15 μg/mL following" exact="hyaluronidase" post="pre-treatment in mice [97]. Studies by several other groups"/>
   <result pre="other groups displayed similar increases in in vivo expression following" exact="hyaluronidase" post="pre-treatment [37, 39, 98]. A recent study by Schommer"/>
   <result pre="in the ECM, describes this enzyme as an alternative to" exact="hyaluronidase" post="[99]. More recent studies have addressed the need for"/>
   <result pre="hyaluronidase [99]. More recent studies have addressed the need for" exact="hyaluronidase" post="pre-treatment and are utilizing co-formulation with recombinant human hyaluronidase"/>
   <result pre="for hyaluronidase pre-treatment and are utilizing co-formulation with recombinant human" exact="hyaluronidase" post="(Hylenex®) in non-human primates [43]. The Zika DMAb phase"/>
   <result pre="the treatment of hematological B-cell lymphoma [113]. Nivolumab (anti-PD1) and" exact="ipilimumab" post="(anti-CTLA4) are two of the most successful checkpoint inhibitors"/>
   <result pre="for Medicare and Medicaid Services (CMS), the mg/kg price for" exact="nivolumab" post="and ipilimulmab was US$28 and US$153, respectively [114]. For"/>
   <result pre="stage III or higher melanoma patient, a combination regimen of" exact="nivolumab" post="and ipilimumab prescribes a 60- and 90-min IV injection"/>
   <result pre="or higher melanoma patient, a combination regimen of nivolumab and" exact="ipilimumab" post="prescribes a 60- and 90-min IV injection every 3"/>
   <result pre="IV injection every 3 weeks for four cycles, followed by" exact="nivolumab" post="every 2 weeks until the patient presents a good"/>
   <result pre="next designed and studied the functionality of DMAb-encoded anti-human CTLA4" exact="ipilimumab" post="and tremelimumab in vitro using donor-derived peripheral blood mononuclear"/>
   <result pre="approach is currently being evaluated in the clinic with recombinant" exact="nivolumab" post="and ipilimumab and is demonstrating greater efficacy in combination,"/>
   <result pre="currently being evaluated in the clinic with recombinant nivolumab and" exact="ipilimumab" post="and is demonstrating greater efficacy in combination, prolonging overall"/>
   <result pre="and re-emerging viral pathogens, and parasitic and fungal diseases. Yet," exact="palivizumab" post="(Synagis), an anti-respiratory syncytical virus mAb, is the only"/>
   <result pre="10 mg/kg IV over 60 min [114]. Two additional mAbs," exact="raxibacumab" post="and obiltoxaximab, have been approved for treatment of inhalational"/>
   <result pre="electroporation (EP) device, they showed the benefit of delivery and" exact="hyaluronidase" post="pre-treatment of the muscle to increase muscle uptake of"/>
   <result pre="and B/HA, respectively) [37]. Using an advanced EP device and" exact="hyaluronidase" post="pre-treatment, the anti-HA DMAbs were expressed to levels of &amp;gt; 10"/>
   <result pre="injection sites) (Fig. 7, magenta), and additional device/delivery optimizations, including" exact="hyaluronidase" post="treatment, have led to further increases, now to levels"/>
   <result pre="human study will deliver DMAb in formulation with recombinant human" exact="hyaluronidase" post="to improve drug dispersion. In parallel, a first-in-human mRNA-mAb"/>
   <result pre="antigen receptor T cellsFront Pharmacol2014523510.3389/fphar.2014.0023525389405 88.MestermannKGiavridisTWeberJRydzekJFrenzSNerreterTet al.The tyrosine kinase inhibitor" exact="dasatinib" post="acts as a pharmacologic on/off switch for CAR T"/>
   <result pre="by muscle after plasmid injection and electroporationMol Ther20049332833610.1016/j.ymthe.2003.12.00715006599 95.AkerstromTVedelKNeedhamJHojmanPKontouEHellstenYet al.Optimizing" exact="hyaluronidase" post="dose and plasmid DNA delivery greatly improves gene electrotransfer"/>
   <result pre="antigen monoclonal antibodyCancer Immunol Immunother201766121577158810.1007/s00262-017-2042-728819703 117.WolchokJDChiarion-SileniVGonzalezRRutkowskiPGrobJJCoweyCLet al.Overall survival with combined" exact="nivolumab" post="and ipilimumab in advanced melanomaN Engl J Med2017377141345135610.1056/NEJMoa170968428889792 118.Administration"/>
   <result pre="antibodyCancer Immunol Immunother201766121577158810.1007/s00262-017-2042-728819703 117.WolchokJDChiarion-SileniVGonzalezRRutkowskiPGrobJJCoweyCLet al.Overall survival with combined nivolumab and" exact="ipilimumab" post="in advanced melanomaN Engl J Med2017377141345135610.1056/NEJMoa170968428889792 118.Administration USFaD. Drugs@FDA:"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="4-part\PMC7216417\results\search\drugs\results.xml">
   <result pre="for 1 h. After incubation, overlay medium (2 mL of EMEM/ 1%" exact="methylcellulose" post="(Wako Pure Chemical Industries Ltd., Osaka, Japan), in 2%"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="4-part\PMC7219742\results\search\drugs\results.xml">
   <result pre="Zealand white rabbit, Charles River) (2:3) supplemented with 5 mM" exact="adenosine" post="triphosphate. The female mosquitoes were allowed to take the"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="4-part\PMC7226564\results\search\drugs\results.xml">
   <result pre="Phage treatment was even helpful in alleviating the symptoms of" exact="dextran" post="sodium sulfate-induced colitis in mice colonized with E. coli"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="4-part\PMC7230963\results\search\drugs\results.xml">
   <result pre="41 (40.1%) patients died. Of the 94 patients who received" exact="oseltamivir" post="therapy, 68 (72.3%) began taking oseltamivir 48 h after"/>
   <result pre="94 patients who received oseltamivir therapy, 68 (72.3%) began taking" exact="oseltamivir" post="48 h after the onset of illness. Of the"/>
   <result pre="conditions, clinical signs and symptoms, antiviral treatment course (oseltamivir or" exact="peramivir" post="therapy), results of laboratory tests and radiography findings at"/>
   <result pre="the 102 patients, three did not receive antiviral therapy (either" exact="oseltamivir" post="or peramivir). Of the 99 patients who received antiviral"/>
   <result pre="the 99 patients who received antiviral therapy, 89 patients received" exact="oseltamivir" post="and five received peramivir; five patients received both oseltamivir"/>
   <result pre="received oseltamivir and five received peramivir; five patients received both" exact="oseltamivir" post="and peramivir during their hospitalization. Of the 94 patients"/>
   <result pre="and five received peramivir; five patients received both oseltamivir and" exact="peramivir" post="during their hospitalization. Of the 94 patients who received"/>
   <result pre="peramivir during their hospitalization. Of the 94 patients who received" exact="oseltamivir" post="therapy, 68 (72.3%) began taking oseltamivir 48 h after"/>
   <result pre="94 patients who received oseltamivir therapy, 68 (72.3%) began taking" exact="oseltamivir" post="48 h after the onset of illness. Among the"/>
   <result pre="B virus infection. Of the 38 deceased patients who received" exact="oseltamivir" post="treatment, 76.3% of patients received oseltamivir more than 48"/>
   <result pre="deceased patients who received oseltamivir treatment, 76.3% of patients received" exact="oseltamivir" post="more than 48 h after onset of the illness"/>
   <result pre="of systematic reviews and/or meta analysesJ. Antimicrob. Chemother.2017722990300710.1093/jac/dkx27128961794 16.FryA.M.GoswamiD.NaharK.SharminA.T.RahmanM.GubarevaL.AzimT.BreseeJ.LubyS.P.BrooksW.A.Efficacy of" exact="oseltamivir" post="treatment started within 5 days of symptom onset to"/>
   <result pre="and Risk Factors for Fatal OutcomePLoS ONE2009410.1371/journal.pone.0006051 32.KumarA.Early versus late" exact="oseltamivir" post="treatment in severely ill patients with 2009 pandemic influenza"/>
   <result pre="N (%) 94 (92.2) 56 (91.8) 38 (92.7) &amp;gt;0.99 Use" exact="oseltamivir" post="≥48 h after onset of illness, N/total N (%)"/>
   <result pre="N (%) 10 (9.8) 8 (13.1) 2 (4.9) 0.793 Use" exact="peramivir" post="≥48 h after onset of illness, N/total N (%)"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="4-part\PMC7232083\results\search\drugs\results.xml">
   <result pre="He was hospitalized for 46 days, received 10 days of" exact="ceftriaxone" post="2 g 12/12 h. During hospitalization, HIV viral load 382,863 copies/μL"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="4-part\PMC7232137\results\search\drugs\results.xml">
   <result pre="loads and symptoms of influenza infection similar to treatment with" exact="oseltamivir" post="(TamifluTM), a neuraminidase inhibitor [123]. However, resistance mutations in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="4-part\PMC7232149\results\search\drugs\results.xml">
   <result pre="Inhibitors The susceptibility of the B/2017 and B/2017-MA strains to" exact="oseltamivir" post="(Hoffmann-La Roche, Basel, Switzerland) was evaluated by published NA"/>
   <result pre="Determination of Anti-Influenza Drugs Efficacy We studied anti-influenza efficacy of" exact="oseltamivir" post="ethoxysuccinate and Tamiflu® on 6–8-week-old BALB/c mice (FSRI SRC"/>
   <result pre="os (oral administration) with a dose of 25 mg/kg/day of" exact="oseltamivir" post="ethoxysuccinate (200 µL in each) during the 5 d.p.i."/>
   <result pre="Vitro and In Vivo Here, we measured the IC50 of" exact="oseltamivir" post="ethoxysuccinate that is necessary to reduce the NA activity"/>
   <result pre="Thus, analysis of the NA inhibition in vitro showed that" exact="oseltamivir" post="ethoxysuccinate and Tamiflu® reduced the neuraminidase activity of the"/>
   <result pre="strain, and then treated per os for 5 days with" exact="oseltamivir" post="ethoxysuccinate or Tamiflu®, were seen (Figure 2F,G). All mice"/>
   <result pre="human influenza virus infection [39,40]. Between the NA inhibitors of" exact="oseltamivir" post="phosphate (Tamiflu®) and zanamivir (Relenza®), the former is considered"/>
   <result pre="[39,40]. Between the NA inhibitors of oseltamivir phosphate (Tamiflu®) and" exact="zanamivir" post="(Relenza®), the former is considered the most effective because"/>
   <result pre="has shown (like Tamiflu®) high effectiveness against the mouse-adapted IBV," exact="oseltamivir" post="ethoxysuccinate is a promising drug for the treatment of"/>
   <result pre="morphologies were also shown. Assessment of the investigational anti-influenza drug" exact="oseltamivir" post="ethoxysuccinate and influenza vaccine Ultrix® showed effectiveness against our"/>
   <result pre="Chemical and Energetic Technologies, Biysk, Russia, for providing antiviral drug" exact="oseltamivir" post="ethoxysuccinate. Construction of the tree was done using sequences"/>
   <result pre="and Biological ActivityMolecules201621151310.3390/molecules2111151327845731 41.BurcevaE.Review of efficacy data and monitoring of" exact="oseltamivir" post="susceptibility to influenza virus strainsVrach Dr.2010126770 42.SatoM.SaitoR.SatoI.TanabeN.ShobugawaY.SasakiA.LiD.SuzukiY.SatoM.SakaiT.et al.Effectiveness of"/>
   <result pre="oseltamivir susceptibility to influenza virus strainsVrach Dr.2010126770 42.SatoM.SaitoR.SatoI.TanabeN.ShobugawaY.SasakiA.LiD.SuzukiY.SatoM.SakaiT.et al.Effectiveness of" exact="oseltamivir" post="treatment among children with influenza A or B virus"/>
   <result pre="infected with 10 MID50 of B/2017-MA strain and treated with" exact="oseltamivir" post="ethoxysuccinate (green line).✶ p &amp;lt; 0.05; ✶✶ p &amp;lt;"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="4-part\PMC7232181\results\search\drugs\results.xml">
   <result pre="media exchange. The NCI-H441 medium was supplemented with 1 µM" exact="dexamethasone" post="(Sigma-Aldrich, Munich, Germany). After 1 week of culture, hMdM"/>
   <result pre="pathogens in a co-infection. Therefore, the mice were anesthetized by" exact="isoflurane" post="inhalation and intranasally inoculated with HA-D222-mpJena/5258 (5 × 104"/>
   <result pre="of pulmonary surfactant in the fetal rabbitJ. Appl. Physiol.19713035836110.1152/jappl.1971.30.3.3585544115 38.GuarinoN.OueT.ShimaH.PuriP.Antenatal" exact="dexamethasone" post="enhances surfactant protein synthesis in the hypoplastic lung of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="4-part\PMC7232189\results\search\drugs\results.xml">
   <result pre="by interfering with functional viral ribonucleoprotein complex assemblyJ. Virol.201286134451345510.1128/JVI.01682-1223015724 39.KronckeK.D.FehselK.Kolb-BachofenV.Inducible" exact="nitric oxide" post="synthase in human diseasesClin. Exp. Immunol.199811314715610.1046/j.1365-2249.1998.00648.x9717962 40.BosworthA.DowallS.D.Garcia-DorivalI.RickettN.Y.BruceC.B.MatthewsD.A.FangY.AljabrW.KennyJ.NelsonC.et al.A comparison"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="4-part\PMC7232439\results\search\drugs\results.xml">
   <result pre="discussed in detail by Sarvestani and his colleagues [143]. Delayed" exact="oseltamivir" post="and sirolimus combined treatment could suppress NLRP3 inflammasome mediated"/>
   <result pre="detail by Sarvestani and his colleagues [143]. Delayed oseltamivir and" exact="sirolimus" post="combined treatment could suppress NLRP3 inflammasome mediated secretion of"/>
   <result pre="in response to various intracellular stress. Several factors such as" exact="nitric oxide" post="(NO), cytochrome c, and second mitochondria-derived activator of caspases"/>
   <result pre="of antiviral responses to influenza A virus infectionAntivir. Res.2017148324210.1016/j.antiviral.2017.10.02029097227 144.JiaX.LiuB.BaoL.LvQ.LiF.LiH.AnY.ZhangX.CaoB.WangC.Delayed" exact="oseltamivir" post="plus sirolimus treatment attenuates H1N1 virus-induced severe lung injury"/>
   <result pre="responses to influenza A virus infectionAntivir. Res.2017148324210.1016/j.antiviral.2017.10.02029097227 144.JiaX.LiuB.BaoL.LvQ.LiF.LiH.AnY.ZhangX.CaoB.WangC.Delayed oseltamivir plus" exact="sirolimus" post="treatment attenuates H1N1 virus-induced severe lung injury correlated with"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="4-part\PMC7232498\results\search\drugs\results.xml">
   <result pre="virus in Thailand during 2010 to 2014PLoS ONE201510e011630210.1371/journal.pone.011630225602617 24.GubarevaL.MatrosovichM.N.BrennerM.K.BethellR.C.WebsterR.G.Evidence for" exact="zanamivir" post="resistance in an immunocompromised child infected with influenza B"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="4-part\PMC7235449\results\search\drugs\results.xml">
   <result pre="Siemens Inveon PET-CT. Briefly, animals were sedated using 1.5% inhaled" exact="isoflurane" post="and injected with [18F]FB-IL-2 (~10 MBq per animal) via"/>
   <result pre="ONNV-infected mice were subjected to a post-infection treatment regimen of" exact="fingolimod" post="(FTY720, 20 μg daily from 2 to 6 dpi)."/>
   <result pre="with no effect on viremia (Figures 5A,B). Figure 5 Therapeutic" exact="fingolimod" post="(FTY720) treatments alleviate ONNV-induced joint pathology by inhibiting CD4+"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="4-part\PMC7235622\results\search\drugs\results.xml">
   <result pre="of harm reduction interventions including syringe exchange programs (SEPs), MOUD," exact="naloxone" post="distribution, and HIV pre-exposure prophylaxis, most remain inaccessible to"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="4-part\PMC7238209\results\search\drugs\results.xml">
   <result pre="Dielmo, SenegalAm. J. Trop. Med. Hyg.2018981343135210.4269/ajtmh.17-000929557325 92.Soleimani-AhmadiM.VatandoostH.ShaeghiM.RaeisiA.AbediF.EshraghianM.R.MadaniA.SafariR.OshaghiM.A.AbtahiM.et al.Field evaluation of" exact="permethrin" post="long-lasting insecticide treated nets (Olyset®) for malaria control in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="4-part\PMC7239338\results\search\drugs\results.xml">
   <result pre="100 antiviral drugs have been approved since the approval of" exact="idoxuridine" post="in 1963 (an anti�?herpes virus drug), these molecules are"/>
   <result pre="of multiple pro�?inflammatory mediators, including TNFα, interleukin (IL)�?1, IL�?6, and" exact="nitric oxide" post="by activated monocytes/macrophages.22 Consistent with EVD pathogenesis, high levels"/>
   <result pre="antiviral efficacy in vitro or in vivo. Combining favipiravir and" exact="ribavirin" post="in Lassa fever Favipiravir was also reported to have"/>
   <result pre="Indeed. several in vitro studies and mice studies showed that" exact="ribavirin" post="may potentiate the efficacy of favipiravir against various RNA"/>
   <result pre="Lassa fever virus infection.78 In order to better understand how" exact="ribavirin" post="may potentiate the efficacy of favipiravir in mice, we"/>
   <result pre="In order to gain information on the potential role of" exact="ribavirin" post="on loss cell death, we assumed that the level"/>
   <result pre="infected cells. We assumed four potential mechanisms of action for" exact="ribavirin" post="that could (i) act as a mutagen limiting the"/>
   <result pre="Our analyses did not find a statistically significant effect of" exact="ribavirin" post="in reducing viral production, however, the best description to"/>
   <result pre="to the data was obtained by assuming an effect of" exact="ribavirin" post="in preventing infected cells from dying. This possibly explains"/>
   <result pre="also explain the viral plateau observed at peak viremia in" exact="ribavirin" post="monotherapy group.80 Thus, our model suggested that ribavirin did"/>
   <result pre="viremia in ribavirin monotherapy group.80 Thus, our model suggested that" exact="ribavirin" post="did not act much as a direct antiviral against"/>
   <result pre="virus, it is unlikely that the combination of favipiravir and" exact="ribavirin" post="is relevant against EBOV, as no gain in terms"/>
   <result pre="new epidemic clusters arising. Likewise, the combination of favipiravir and" exact="ribavirin" post="in Lassa virus hemorrhagic fever could be of relevance"/>
   <result pre="9Oestereich, L.et alEfficacy of favipiravir alone and in combination with" exact="ribavirin" post="in a lethal, immunocompetent mouse model for Lassa fever."/>
   <result pre="66Dixit, N.M., Layden�?Almer, J.E., Layden, T.J. &amp;amp; Perelson, A.S.Modelling how" exact="ribavirin" post="improves interferon response rates in hepatitis C virus infection."/>
   <result pre="kinetic and modeling analyses indicate similar time to cure among" exact="sofosbuvir" post="combination regimens with daclatasvir, simeprevir or ledipasvir. J. Hepatol.64,"/>
   <result pre="similar time to cure among sofosbuvir combination regimens with daclatasvir," exact="simeprevir" post="or ledipasvir. J. Hepatol.64, 1232–1239 (2016).26907973 68Madelain, V.et alEbola"/>
   <result pre="in macaques. Emerg. Infect. Dis.24, 1696–1699 (2018).29882740 77Westover, J.B.et alLow�?dose" exact="ribavirin" post="potentiates the antiviral activity of favipiravir against hemorrhagic fever"/>
   <result pre="fever viruses. Antiviral Res.126, 62–68 (2016).26711718 78Raabe, V.N.et alFavipiravir and" exact="ribavirin" post="treatment of epidemiologically linked cases of Lassa fever. Clin."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="4-part\PMC7239382\results\search\drugs\results.xml">
   <result pre="limited number of experiments, mice were briefly anesthetized using 20%" exact="isoflurane" post="before they were injected intranasally (i.n.) with 50 ng"/>
   <result pre="were vaccinated i.n. using 20 μL of FluMist under light" exact="isoflurane" post="anesthesia. To study recall TCD8 responses to IAV, mice"/>
   <result pre="109 colony-forming units (CFUs)/mL in Hank’s Balanced Salt Solution. Under" exact="isoflurane" post="anesthesia, mice were instilled i.n. with 25 μL of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="4-part\PMC7242466\results\search\drugs\results.xml">
   <result pre="detailed in Supplementary Table 3. Furthermore, 96.4% of patients received" exact="oseltamivir" post="antiviral treatment, and 89.3% received antibiotics originating from the"/>
   <result pre="and nasal wash samples were done on ferrets anesthetized with" exact="ketamine" post="(25 mg/kg) and xylazine (2 mg/kg) intramuscularly. A detailed time point"/>
   <result pre="Physiol. Lung Cell Mol. Physiol.2015309L1047L105526432870 27.HeiraliAAet al.The effects of inhaled" exact="aztreonam" post="on the cystic fibrosis lung microbiomeMicrobiome201755128476135 28.RelmanDAThe human microbiome:"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="4-part\PMC7243378\results\search\drugs\results.xml">
   <result pre="and improved survival. We provided evidence for the use of" exact="doxycycline" post="for coverage of atypical pathogens in nonsevere pneumonia. In"/>
   <result pre="with a macrolide is recommended. For patients with severe pneumonia," exact="ceftriaxone" post="or piperacillin-tazobactam, with a macrolide, are recommended. Empirical fluoroquinolone"/>
   <result pre="The majority of patients were prescribed empirical amoxicillin-clavulanate (79%) or" exact="ceftriaxone" post="(8%) with or without doxycycline. Empirical coverage for atypical"/>
   <result pre="patients. Forty-four patients with severe pneumonia/bronchiectasis were prescribed amoxicillin-clavulanate or" exact="ceftriaxone" post="with or without doxycycline, or piperacillin-tazobactam monotherapy without macrolide."/>
   <result pre="most common atypical pathogen, supporting the recommendation of amoxicillin-clavulanate and" exact="doxycycline" post="for hospitalized nonsevere CAP. Macrolide resistance secondary to A2063G"/>
   <result pre="for atypical pathogens, 88% were given doxycycline. The use of" exact="doxycycline" post="as part of a combination therapy for CAP for"/>
   <result pre="fluoroquinolones [4]. In a retrospective study in San Francisco, empirical" exact="ceftriaxone" post="and doxycycline reduced in-patient and 30-day mortality in patients"/>
   <result pre="In a retrospective study in San Francisco, empirical ceftriaxone and" exact="doxycycline" post="reduced in-patient and 30-day mortality in patients hospitalized for"/>
   <result pre="other antibiotic regimens [21]. In another retrospective study in Australia," exact="doxycycline" post="was shown to have comparable effects on outcomes compared"/>
   <result pre="high macrolide resistance in atypical pathogens. However, the role of" exact="doxycycline" post="in severe pneumonia is uncertain and needs further evaluation."/>
   <result pre="Eur Respir J2007; 29:751–6.17005580 21.FlandersSA, DudasV, KerrK, et al.Effectiveness of" exact="ceftriaxone" post="plus doxycycline in the treatment of patients hospitalized with"/>
   <result pre="J2007; 29:751–6.17005580 21.FlandersSA, DudasV, KerrK, et al.Effectiveness of ceftriaxone plus" exact="doxycycline" post="in the treatment of patients hospitalized with community-acquired pneumonia."/>
   <result pre="al.The etiology of community-acquired pneumonia in Australia: why penicillin plus" exact="doxycycline" post="or a macrolide is the most appropriate therapy. Clin"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="4-part\PMC7245076\results\search\drugs\results.xml">
   <result pre="infectious virus production. PLoS Pathog.12, e1005886 (2016).27622521 22YinZ.et al., An" exact="adenosine" post="nucleoside inhibitor of dengue virus. Proc. Natl. Acad. Sci."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="4-part\PMC7247188\results\search\drugs\results.xml">
   <result pre="Sichuan and Yunnan. In China, the recommended first-line regimen was" exact="zidovudine" post="(AZT) or stavudine (D4T) + lamivudine (3TC) + nevirapine (NVP) in 2005 [22]"/>
   <result pre="In China, the recommended first-line regimen was zidovudine (AZT) or" exact="stavudine" post="(D4T) + lamivudine (3TC) + nevirapine (NVP) in 2005 [22] and D4T was"/>
   <result pre="2005 [22] and D4T was gradually replaced by AZT or" exact="tenofovir" post="(TDF) from 2010 [37]. The current first-line regimen was"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="4-part\PMC7248559\results\search\drugs\results.xml">
   <result pre="containing 8% FCS and antibiotics (100 μg/ml penicillin, 100 μg/ml" exact="streptomycin" post="and 250 μg/ml amphotericin B) (Lonza, USA). Focus selection"/>
   <result pre="of a second round of selection in the absence of" exact="mycophenolic acid" post="(MPA) selection pressure, resulting in a product free from"/>
   <result pre="Material 1) (24). Selection of foci with EGFP expression under" exact="mycophenolic acid" post="(MPA) selection pressure was achieved through multiple rounds of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="4-part\PMC7252251\results\search\drugs\results.xml">
   <result pre="penicillin–streptomycin combinations, β-lactams, and carbacephems. Among all the antibiotics, tetracycline," exact="sulfamethoxazole" post="(sulfonamide), streptomycin (aminoglycoside), azithromycin, clarithromycin (macrolide), ciprofloxacin (fluoroquinolone), and"/>
   <result pre="β-lactams, and carbacephems. Among all the antibiotics, tetracycline, sulfamethoxazole (sulfonamide)," exact="streptomycin" post="(aminoglycoside), azithromycin, clarithromycin (macrolide), ciprofloxacin (fluoroquinolone), and amoxicillin (β-lactam)"/>
   <result pre="Among all the antibiotics, tetracycline, sulfamethoxazole (sulfonamide), streptomycin (aminoglycoside), azithromycin," exact="clarithromycin" post="(macrolide), ciprofloxacin (fluoroquinolone), and amoxicillin (β-lactam) are the most"/>
   <result pre="the antibiotics, tetracycline, sulfamethoxazole (sulfonamide), streptomycin (aminoglycoside), azithromycin, clarithromycin (macrolide)," exact="ciprofloxacin" post="(fluoroquinolone), and amoxicillin (β-lactam) are the most extensively utilized"/>
   <result pre="sulfamethoxazole (sulfonamide), streptomycin (aminoglycoside), azithromycin, clarithromycin (macrolide), ciprofloxacin (fluoroquinolone), and" exact="amoxicillin" post="(β-lactam) are the most extensively utilized ones as medicine"/>
   <result pre="ubiquitous nature and persistence in the aqueous environment. Among all," exact="carbamazepine" post="is one of the most widely prescribed medicines to"/>
   <result pre="detected in both WWTP effluents and river water. In fact," exact="carbamazepine" post="can be completely transformed during metabolism. Normally, less than"/>
   <result pre="by human being. Therefore high concentrations of the metabolites of" exact="carbamazepine" post="are detected instead of the parent compound in WWTPs"/>
   <result pre="in the following sections. 3.3.1.1 Antibiotic resistance genes related to" exact="tetracycline" post="The application of tetracycline has induced the development of"/>
   <result pre="3.3.1.1 Antibiotic resistance genes related to tetracycline The application of" exact="tetracycline" post="has induced the development of ARGs related to tetracycline"/>
   <result pre="of tetracycline has induced the development of ARGs related to" exact="tetracycline" post="in the environment. In recent years, tetracycline resistance genes"/>
   <result pre="ARGs related to tetracycline in the environment. In recent years," exact="tetracycline" post="resistance genes encoding ribosome protective proteins including tetM, O,"/>
   <result pre="natural water environments [34]. To date, at least 38 different" exact="tetracycline" post="resistance genes (tet) and 3 oxytetracycline resistance genes (otr)"/>
   <result pre="at least 38 different tetracycline resistance genes (tet) and 3" exact="oxytetracycline" post="resistance genes (otr) have been identified [35]. These genes"/>
   <result pre="to have good interspecies transfer ability. The environmental microbial antioxidant" exact="tetracycline" post="plasmids TetA, D, and M can also be transferred"/>
   <result pre="and urban surface waters. Aminoglycoside ARGs encoding antibiotics (neomycin-resistant and" exact="streptomycin" post="phosphorous transferase genes) are found in rivers of Canada."/>
   <result pre="Canada. 3.3.1.3 Antibiotic resistance genes related to macrolide–lincosamide–streptogramin, chloramphenicol, and" exact="vancomycin" post="Although macrolide, lincosamide, and streptogramin are structurally unrelated, macrolide-resistance"/>
   <result pre="60 different genes are resistant to one or more macrolide" exact="streptomycin" post="(MLS) antibiotics. It includes methylation, excretion, and related genes"/>
   <result pre="enterococci and streptococcal SPP strains [37]. The resistance mechanisms of" exact="chloramphenicol" post="and fluorophenol include chloramphenicol acetyltransferase (encoded by the cat"/>
   <result pre="strains [37]. The resistance mechanisms of chloramphenicol and fluorophenol include" exact="chloramphenicol" post="acetyltransferase (encoded by the cat gene), specific exporters (encoded"/>
   <result pre="microorganisms exists. 3.3.1.4 Antibiotic resistance genes related to sulfonamides and" exact="trimethoprim" post="Sulfonamides are the most widely used antibiotics in clinical"/>
   <result pre="These two biological enzymes are responsible for the biosynthesis of" exact="folic acid" post="to some extent. They could impact on the production"/>
   <result pre="production of thymine and the growth of microorganisms. Sulfonamides and" exact="trimethoprim" post="resistance are generally encoded by mutations located in highly"/>
   <result pre="including aad (or aac) encoding amino glucoside nucleoside transferase, encoding" exact="chloramphenicol" post="CML of the effluent, and cat encoding chloramphenicol acetyltransferase"/>
   <result pre="transferase, encoding chloramphenicol CML of the effluent, and cat encoding" exact="chloramphenicol" post="acetyltransferase [38]. 3.3.2 The impact of antibiotic resistance genes"/>
   <result pre="It was reported that the removal rate of antiepileptic drug" exact="carbamazepine" post="was only 8% and the removal rate of cholesterol-lowering"/>
   <result pre="was only 8% and the removal rate of cholesterol-lowering drug" exact="clofibrate" post="almost zero [46], [47]. It suggests that the residual"/>
   <result pre="antibiotics commonly used in medicine such as ciprofloxacin, ofloxacin, and" exact="metronidazole" post="are almost impossible to be biodegraded in water, and"/>
   <result pre="the aquatic organisms such as fish [63]. The presence of" exact="cyclophosphamide" post="and ifosfamide in water could induce cancer risk to"/>
   <result pre="organisms such as fish [63]. The presence of cyclophosphamide and" exact="ifosfamide" post="in water could induce cancer risk to humans. In"/>
   <result pre="removal efficiencies of codeine, pravastatin, ketoprofen, diclofenac, roxithromycin, gemfibrozil, and" exact="iohexol" post="were greater than 95%, which almost remained the same"/>
   <result pre="antibiotics from wastewater by electrocoagulationChemosphere194201838138929223117 46NkoomM.LuG.LiuJ.YangH.DongH.Bioconcentration of the antiepileptic drug" exact="carbamazepine" post="and its physiological and biochemical effects on Daphnia magnaEcotoxicol."/>
   <result pre="case of studyEstuar. Coast. Shelf Sci.17820161220 59AşicioğluO.GungordukK.OzdemirA.ErtasI.E.YildirimG.SanciM.Single daily dose of" exact="moxifloxacin" post="versus ofloxacin plus metronidazole as a new treatment approach"/>
   <result pre="studyEstuar. Coast. Shelf Sci.17820161220 59AşicioğluO.GungordukK.OzdemirA.ErtasI.E.YildirimG.SanciM.Single daily dose of moxifloxacin versus" exact="ofloxacin" post="plus metronidazole as a new treatment approach to uncomplicated"/>
   <result pre="Shelf Sci.17820161220 59AşicioğluO.GungordukK.OzdemirA.ErtasI.E.YildirimG.SanciM.Single daily dose of moxifloxacin versus ofloxacin plus" exact="metronidazole" post="as a new treatment approach to uncomplicated pelvic inflammatory"/>
   <result pre="the cancer risk to humans resulting from the presence of" exact="cyclophosphamide" post="and ifosfamide in surface waterEnviron. Sci. Pollut. Res.1722010486496 65RyszM.AlvarezP.J.J.Amplification"/>
   <result pre="risk to humans resulting from the presence of cyclophosphamide and" exact="ifosfamide" post="in surface waterEnviron. Sci. Pollut. Res.1722010486496 65RyszM.AlvarezP.J.J.Amplification and attenuation"/>
   <result pre="in surface waterEnviron. Sci. Pollut. Res.1722010486496 65RyszM.AlvarezP.J.J.Amplification and attenuation of" exact="tetracycline" post="resistance in soil bacteria: aquifer column experimentsWater Res.381720043705371215350422 66MousaabA.ClaireC.MagaliC.ChristopheD.Upgrading"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="4-part\PMC7252634\results\search\drugs\results.xml">
   <result pre="was allowed to proceed for 1.5 h and then 1%" exact="methylcellulose" post="overlay prepared in DMEM with 2% FBS was added"/>
   <result pre="were performed under anesthesia that was induced and maintained with" exact="ketamine" post="hydrochloride and xylazine, and all efforts were made to"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="4-part\PMC7252670\results\search\drugs\results.xml">
   <result pre="medium supplemented with 10% of FBS and 3.2% of carboxyl" exact="methylcellulose" post="(Sigma-Aldrich) was added. The plate was then incubated for"/>
   <result pre="suspension at 3x107 FFU/mL (final concentration at 107 FFU/mL). An" exact="adenosine" post="triphosphate phagostimulant (Sigma-Aldrich), was added at a final concentration"/>
   <result pre="broth and antibiotics/antifungals (100 units/mL of penicillin, 0.1 mg/mL of" exact="streptomycin" post="and 0.25 μg/mL amphotericin B, Gibco, ThermoFisher Scientific). The"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="4-part\PMC7254658\results\search\drugs\results.xml">
   <result pre="10.1186/s12981-020-00285-0 : Research A prospective cohort study of outcomes for" exact="isoniazid" post="prevention therapy: a nested study from a national QI"/>
   <result pre="to reduce incident TB in PLHIV, besides early ART initiation," exact="isoniazid" post="preventive therapy (IPT) is the key intervention to prevent"/>
   <result pre="appointment visit. Only 4% of patients experienced side effects of" exact="isoniazid" post="(INH) but none of them developed active TB at"/>
   <result pre="remain very susceptible to TB. Therefore, besides early ART initiation," exact="isoniazid" post="preventive therapy (IPT) is the key intervention to prevent"/>
   <result pre="are contained in Table 3. Table 3 Primary outcomes for" exact="isoniazid" post="prevention therapy Patient characteristics Numbers (n) Percentages (%) Developed"/>
   <result pre="contained in Table 4. Table 4 Covariates of completion of" exact="isoniazid" post="prevention therapy Variable Coefficient p-value df AOR 95% CI"/>
   <result pre="are undernourished and can be prevented with concurrent prescription of" exact="pyridoxine" post="(vitamin B6) [14]. Blurred or loss of vision, convulsions,"/>
   <result pre="HIV positive patients in Addis AbabaEthiopia Adv Epidemiol.201420141610.1155/2014/230587 8.TramKHMwangwaFAtukundaMOwaraganiseAAyiekoJPlentyAKwariisimaDClarkTDPetersenMLCharleboisEDKamyaMRChamieGHavlirDVMarquezCsearch collaboration" exact="isoniazid" post="preventive therapy completion in the era of differentiated HIV"/>
   <result pre="in Kinshasa, Democratic Republic of CongoAIDS.2015291510.1097/QAD.0000000000000831 10.MunseriPJTalbotEAMteiLFordham von ReynCCompletion of" exact="isoniazid" post="preventive therapy among HIV-infected patients in TanzaniaInt J Tuberc"/>
   <result pre="patients in TanzaniaInt J Tuberc Lung Dis.20081291037104118713501 11.DurovniBCavalcanteSCSaraceniVVellozoVIsraelGKingBSCohnSEfronAPachecoAGMoultonLHChaissonREGolubJEThe implementation of" exact="isoniazid" post="preventive therapy in HIV clinics: the experience from the"/>
   <result pre="AfricaAIDS.201024111679168710.1097/QAD.0b013e32833a097b20453629 14.Van der WattJJHarrisonTBBenatarMHeckmannJMPolyneuropathy, anti-tuberculosis treatment and the role of" exact="pyridoxine" post="in the HIV/AIDS era: a systematic reviewInt J Tuberc"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="4-part\PMC7255596\results\search\drugs\results.xml">
   <result pre="All procedures were conducted under anesthesia by intramuscular injection of" exact="ketamine" post="at 10–20 mg/kg-1 of body weight, as approved by"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="4-part\PMC7256184\results\search\drugs\results.xml">
   <result pre="the patients received antiviral therapy (acyclovir or ribavirin) and intravenous" exact="methylprednisolone" post="at a dose of 20 mg/kg/day (1 g maximum)"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="4-part\PMC7258707\results\search\drugs\results.xml">
   <result pre="that modulates host response by producing increased levels of cyclic" exact="adenosine" post="monophosphate (cAMP) and causing severe edema in infected host"/>
   <result pre="available for prevention or treatment of human disease, and while" exact="ribavirin" post="is sometimes used to treat Lassa fever, it is"/>
   <result pre="Screening of a small molecule library in this assay identified" exact="rifabutin" post="and ethavarine, as potential inhibitors of B. pseudomallei (Bp82)"/>
   <result pre="not reported, but likely high due to structure similarity to" exact="toremifene" post="Estrogen receptor modulator, human-free drug exposure = Ebola EC50"/>
   <result pre="triphosphorylated to the active drug. In humans, plasma concentrations of" exact="ribavirin" post="have been correlated to virological response Nucleoside drug; FDA"/>
   <result pre="to mice up to 250 mg/kg Nucleoside monophosphate prodrug of" exact="zidovudine" post="(AZT) [116] LASV, JUNV LHF-535 Entry inhibitor In vitro—yield"/>
   <result pre="Clindamycin Treatment of rabbits with systemic anthrax with clindamycin and" exact="ciprofloxacin" post="had improved efficacy compared to monotherapy and could be"/>
   <result pre="therapy for anthrax, including antiprotective antigen (PA IgG) antibodies and" exact="ciprofloxacin" post="in a rodent anthrax model increased survival significantly compared"/>
   <result pre="in a rodent anthrax model increased survival significantly compared to" exact="ciprofloxacin" post="treatment alone [157] Levofloxacin Raxibacumab Combination therapy with raxibacumab,"/>
   <result pre="IgG1 monoclonal antibody that binds protective antigen, and the antibiotic" exact="levofloxacin" post="provides protection in rabbits late in the disease course"/>
   <result pre="meropenem, or rifampin Linezolid Treatment of antibiotic-resistant inhalation anthrax with" exact="linezolid" post="and penicillin, meropenem, or rifampin had the inhibitory effect"/>
   <result pre="combination therapies used to treat pulmonary brucellosis in humans is" exact="doxycycline" post="and rifampin for 6 weeks [162] Burkholderia mallei Antibiotic"/>
   <result pre="antibiotic therapy to inhibit bacterial growth [163] Enrofloxacin, trimethoprim, and" exact="sulfadiazine" post="Doxycycline Successful 12-week combination treatment of parenteral administration of"/>
   <result pre="Successful 12-week combination treatment of parenteral administration of enrofloxacin and" exact="trimethoprim" post="with sulfadiazine followed by oral administration of doxycycline eliminated"/>
   <result pre="combination treatment of parenteral administration of enrofloxacin and trimethoprim with" exact="sulfadiazine" post="followed by oral administration of doxycycline eliminated B. mallei"/>
   <result pre="enrofloxacin and trimethoprim with sulfadiazine followed by oral administration of" exact="doxycycline" post="eliminated B. mallei from glanderous horses during an outbreak"/>
   <result pre="in vitro [165], [166] Ceftazidime Avibactam Avibactam restores susceptibility to" exact="ceftazidime" post="for genetically diverse extremely drug resistant isolates of Burkholderia"/>
   <result pre="isolates [166] Ceftazidime IFN-γ Interferon gamma–induced reactive oxygen species with" exact="ceftazidime" post="leads to synergistic killing of intracellular B. pseudomallei and"/>
   <result pre="equine antitoxin [169] Coxiella burnetii Doxycycline Chloroquine Combination therapy of" exact="doxycycline" post="and hydroxychloroquine combination shortened the duration of therapy and"/>
   <result pre="[169] Coxiella burnetii Doxycycline Chloroquine Combination therapy of doxycycline and" exact="hydroxychloroquine" post="combination shortened the duration of therapy and reduced the"/>
   <result pre="prosthetic aortic valve and aortic homograft was successfully treated with" exact="doxycycline" post="and chloroquine combination therapy [170], [171] Francisella tularensis Antibiotics"/>
   <result pre="valve and aortic homograft was successfully treated with doxycycline and" exact="chloroquine" post="combination therapy [170], [171] Francisella tularensis Antibiotics Uptake inhibitors"/>
   <result pre="Ciprofloxacin L-97-1 A novel postexposure medical countermeasure l-97-1, an A1" exact="adenosine" post="receptor antagonist blocks LPS-induced activation of immunomodulatory cytotoxic substance"/>
   <result pre="accumulation to prevent acute lung injury, and in combination with" exact="ciprofloxacin" post="improves survival of rats following infection with Y. pestis"/>
   <result pre="with poly(I:C), challenged with F. tularensis, and then treated with" exact="levofloxacin" post="showed 100% survival relative to no survival in animals"/>
   <result pre="showed 100% survival relative to no survival in animals receiving" exact="levofloxacin" post="alone [204]. Figure 7.5 Potentiating immune response by activating"/>
   <result pre="the potential to be repurposed as antiinfectives. Trifluoperazine (an antipsychotic)," exact="amoxapine" post="(an antidepressant), and doxapram (a breathing stimulant) mitigated fatal"/>
   <result pre="repurposed as antiinfectives. Trifluoperazine (an antipsychotic), amoxapine (an antidepressant), and" exact="doxapram" post="(a breathing stimulant) mitigated fatal Y. pestis infection in"/>
   <result pre="bubonic or pneumonic plague agents when administered in combination with" exact="levofloxacin" post="[208]. Multiple FDA-approved drugs targeting G-protein coupled receptors and"/>
   <result pre="the case of biothreat bacteria, the combination of Ceftolozone and" exact="tazobactam" post="exhibited increased in vitro susceptibility to a variety of"/>
   <result pre="Nipah virusMicrobes Infect212019 27GonzalezJ.P.EmonetS.de LamballerieX.CharrelR.ArenavirusesCurr Top Microbiol Immunol315200725328817848068 28RaabeV.N.KannG.RibnerB.S.MoralesA.VarkeyJ.B.MehtaA.K.Favipiravir and" exact="ribavirin" post="treatment of epidemiologically linked cases of Lassa feverClin Infect"/>
   <result pre="life into West Nile virus therapeutics; discovery and study of" exact="zafirlukast" post="as an NS2B-NS3 protease inhibitorEur J Med Chem15720181202121330193218 70QinQ.M.PeiJ.AnconaV.ShawB.D.FichtT.A.de"/>
   <result pre="pathogenesis and treatment with ribavirinJ Infect Dis141519805805896768812 114MorelloJ.Rodriguez-NovoaS.Jimenez-NacherI.SorianoV.Usefulness of monitoring" exact="ribavirin" post="plasma concentrations to improve treatment response in patients with"/>
   <result pre="rabbitsAntimicrob Agents Chemother591220157497750326392505 157KarginovV.A.RobinsonT.M.RiemenschneiderJ.GoldingB.KennedyM.ShiloachJ.Treatment of anthrax infection with combination of" exact="ciprofloxacin" post="and antibodies to protective antigen of Bacillus anthracisFEMS Immunol"/>
   <result pre="antigen of Bacillus anthracisFEMS Immunol Med Microbiol4012004717414734189 158MigoneT.S.BolmerS.ZhongJ.CoreyA.VasconcelosD.BuccellatoM.Added benefit of" exact="raxibacumab" post="to antibiotic treatment of inhalational anthraxAntimicrob Agents Chemother59220151145115125487792 159FossM.H.WeibelD.B.Oligochlorophens"/>
   <result pre="an extremely drug resistant (XDR) pathogen: avibactam restores susceptibility to" exact="ceftazidime" post="for burkholderia cepacia complex isolates from cystic fibrosis patientsACS"/>
   <result pre="Infect Dis37201750251128264560 167MosovskyK.SilvaE.TroyerR.Propst-GrahamK.DowS.Interaction of Interferon gamma-induced reactive oxygen species with" exact="ceftazidime" post="leads to synergistic killing of intracellular Burkholderia pseudomalleiAntimicrob Agents"/>
   <result pre="DupontH.RissJ.M.Arditi-DjianeJ.BrouquiP.Treatment of Q fever endocarditis: comparison of 2 regimens containing" exact="doxycycline" post="and ofloxacin or hydroxychloroquineArch Intern Med159219991671739927100 171CalzaL.AttardL.ManfrediR.ChiodoF.Doxycycline and chloroquine"/>
   <result pre="Q fever endocarditis: comparison of 2 regimens containing doxycycline and" exact="ofloxacin" post="or hydroxychloroquineArch Intern Med159219991671739927100 171CalzaL.AttardL.ManfrediR.ChiodoF.Doxycycline and chloroquine as treatment"/>
   <result pre="containing doxycycline and ofloxacin or hydroxychloroquineArch Intern Med159219991671739927100 171CalzaL.AttardL.ManfrediR.ChiodoF.Doxycycline and" exact="chloroquine" post="as treatment for chronic Q fever endocarditisJ Infect452200212712912217721 172D’EliaR.JennerD.C.LawsT.R.StokesM.G.JacksonM.C.Essex-LoprestiA.E.Inhibition"/>
   <result pre="resistance in Brucella melitensisInt J Antimicrob Agents3412009768119261448 185ValdezateS.NavarroA.Medina-PascualM.J.CarrascoG.Saez-NietoJ.A.Molecular screening for" exact="rifampicin" post="and fluoroquinolone resistance in a clinical population of Brucella"/>
   <result pre="187WebbJ.R.PriceE.P.CurrieB.J.SarovichD.S.Loss of methyltransferase function and increased efflux activity leads to" exact="doxycycline" post="resistance in Burkholderia pseudomalleiAntimicrob Agents Chemother6162017 188ChirakulS.NorrisM.H.PagdepanichkitS.SomprasongN.RandallL.B.ShirleyJ.F.Transcriptional and post-transcriptional"/>
   <result pre="Rep8120181065230006637 189SarovichD.S.WebbJ.R.PitmanM.C.VibergL.T.MayoM.BairdR.W.Raising the stakes: loss of efflux pump regulation decreases" exact="meropenem" post="susceptibility in Burkholderia pseudomalleiClin Infect Dis672201824325029394337 190SarovichD.S.PriceE.P.Von SchulzeA.T.CookJ.M.MayoM.WatsonL.M.Characterization of"/>
   <result pre="meropenem susceptibility in Burkholderia pseudomalleiClin Infect Dis672201824325029394337 190SarovichD.S.PriceE.P.Von SchulzeA.T.CookJ.M.MayoM.WatsonL.M.Characterization of" exact="ceftazidime" post="resistance mechanisms in clinical isolates of Burkholderia pseudomallei from"/>
   <result pre="isolates of Burkholderia pseudomallei from AustraliaPLoS One722012e3078922363490 191ChantratitaN.RhollD.A.SimB.WuthiekanunV.LimmathurotsakulD.AmornchaiP.Antimicrobial resistance to" exact="ceftazidime" post="involving loss of penicillin-binding protein 3 in Burkholderia pseudomalleiProc"/>
   <result pre="A108412011171651717021969582 192CummingsJ.E.SlaydenR.A.Transient in vivo resistance mechanisms of Burkholderia pseudomallei to" exact="ceftazidime" post="and molecular markers for monitoring treatment responsePLoS Negl Trop"/>
   <result pre="Antimicrob Chemother492200237938211815583 197VranakisI.De BockP.J.PapadiotiA.TselentisY.GevaertK.TsiotisG.Quantitative proteome profiling of C. burnetii under" exact="tetracycline" post="stress conditionsPLoS One732012e3359922438959 198LoVulloE.D.SherrillL.A.PerezL.L.PavelkaM.S.Jr.Genetic tools for highly pathogenic Francisella"/>
   <result pre="host-directed therapy against infectious diseasesNat Rev Immunol192201910411730487528 211NapierR.J.NorrisB.A.SwimmA.GiverC.R.HarrisW.A.LavalJ.Low doses of" exact="imatinib" post="induce myelopoiesis and enhance host anti-microbial immunityPLoS Pathog1132015e100477025822986 212ShiY.HeX.ZhuG.TuH.LiuZ.LiW.Coxsackievirus"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="4-part\PMC7259790\results\search\drugs\results.xml">
   <result pre="within the autophagy pathway [24]. All drugs were prepared in" exact="dimethyl sulfoxide" post="(DMSO) and stored at -20°C. Immunoblots Two days after"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="4-part\PMC7261188\results\search\drugs\results.xml">
   <result pre="study of Pimodivir (JNJ-63623872) as monotherapy or in combination with" exact="oseltamivir" post="for treatment of acute uncomplicated seasonal influenza A: TOPAZ"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="4-part\PMC7266814\results\search\drugs\results.xml">
   <result pre="boosting the immunity of human Vγ9Vδ2-T cells with the phosphoantigen" exact="pamidronate" post="could be a therapeutic strategy to treat seasonal and"/>
   <result pre="a recombinant human CD137L protein boosted the therapeutic effects of" exact="pamidronate" post="against influenza virus. Our study provides a novel strategy"/>
   <result pre="of isoprenoid biosynthesis pathways.13 Pharmacological compounds, such as the aminobisphosphonates" exact="pamidronate" post="(PAM) and zoledronate, which are commonly used for the"/>
   <result pre="cells to produce influenza virus-specific antibodyFront. Immunol.2018959929670614 21.TuWet al.The aminobisphosphonate" exact="pamidronate" post="controls influenza pathogenesis by expanding a gammadelta T cell"/>
   <result pre="in humanized miceJ. Exp. Med.20112081511152221708931 22.ZhengJet al.The therapeutic effect of" exact="pamidronate" post="on lethal avian influenza A H7N9 virus infected humanized"/>
   <result pre="cancer vaccinesCancer Res.2014746441645125252915 42.DieliFet al.Targeting human γδ T cells with" exact="zoledronate" post="and interleukin-2 for immunotherapy of hormone-refractory prostate cancerCancer Res.200767745017671215"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="4-part\PMC7268205\results\search\drugs\results.xml">
   <result pre="M2 protein in being insensitive to channel blockers such as" exact="amantadine" post="resulting in natural resistance of type B influenza viruses"/>
   <result pre="this first generation class of anti-influenza compounds. The resistance to" exact="amantadine" post="was explained by differences in the interior part of"/>
   <result pre="viral RNA polymerase. The neuraminidase inhibitors (NAI) include the oral" exact="oseltamivir" post="(given as the prodrug oseltamivir phosphate), the inhaled zanamivir"/>
   <result pre="inhibitors (NAI) include the oral oseltamivir (given as the prodrug" exact="oseltamivir" post="phosphate), the inhaled zanamivir and the intravenous peramivir, which"/>
   <result pre="oral oseltamivir (given as the prodrug oseltamivir phosphate), the inhaled" exact="zanamivir" post="and the intravenous peramivir, which all target the substrate"/>
   <result pre="higher compared to concentrations needed to inhibit IAV NA. For" exact="oseltamivir" post="this observation has been explained by a lower flexibility"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="4-part\PMC7268706\results\search\drugs\results.xml">
   <result pre="Zhi201536993494026814857 19.WangBXZhangLWangYJet al.Epidemiology of syphilis infection among drug users at" exact="methadone" post="maintenance treatment clinics in China: systematic review and meta-analysisInt"/>
   <result pre="in the characteristics of and high-risk behaviours among non-injecting heterosexual" exact="methamphetamine" post="users in Qingdao, Shandong Province, ChinaBMC Public Health2013133010.1186/1471-2458-13-3023311624 21.MutagomaMNyirazinyoyeLSebuhoroDet"/>
   <result pre="J STD AIDS2018291303710.1177/095646241771517428697679 35.LiaoMKangDTaoXet al.Syndemics of syphilis, HCV infection, and" exact="methamphetamine" post="use along the east coast of ChinaBMC Public Health20141417210.1186/1471-2458-14-17224533587"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="4-part\PMC7271460\results\search\drugs\results.xml">
   <result pre="widely available for the adult population, anti-retroviral therapy (ART) based-on" exact="tenofovir" post="(TDF), lamivudine (3TC) and efavirenz (EFV) has dual treatment"/>
   <result pre="for the adult population, anti-retroviral therapy (ART) based-on tenofovir (TDF)," exact="lamivudine" post="(3TC) and efavirenz (EFV) has dual treatment benefits for"/>
   <result pre="population, anti-retroviral therapy (ART) based-on tenofovir (TDF), lamivudine (3TC) and" exact="efavirenz" post="(EFV) has dual treatment benefits for both HBV and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="4-part\PMC7273724\results\search\drugs\results.xml">
   <result pre="then centrifuged to clarify the lysate and run on an" exact="iodixanol" post="(OptiPrep Sigma D1556) gradient (51). Virus was then concentrated"/>
   <result pre="(Sigma S8761), 1% (v/v) HEPES (Sigma H0887), 0.5% (w/v) DEAE" exact="dextran" post="(Sigma 93556), 1% (v/v) Pen-Strep (Sigma P0781), 1% (v/v)"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="4-part\PMC7279256\results\search\drugs\results.xml">
   <result pre="transplants, HEV progresses to chronic hepatitis. Immunosuppressive drugs such as" exact="tacrolimus" post="are a major cause of chronic hepatitis and reducing"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="4-part\PMC7279404\results\search\drugs\results.xml">
   <result pre="NPC1L1 in the regulation of hepatic metabolism: Potential contribution of" exact="ezetimibe" post="in NAFLD/NASH treatmentCurr. Vasc. Pharmacol.2011912112310.2174/15701611179374471521044016 62.ZhaoY.ZhaoM.F.JiangS.WuJ.LiuJ.YuanX.W.ShenD.ZhangJ.Z.ZhouN.HeJ.et al.Liver governs adipose"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="4-part\PMC7283535\results\search\drugs\results.xml">
   <result pre="a result of inherent structural or functional characteristics. For example," exact="vancomycin" post="(glycopeptide antibiotic) which inhibits peptidoglycan crosslinking, is generally effective"/>
   <result pre="some P. aeruginosa isolates the ability to became resistant to" exact="carbenicillin" post="antibiotics. Moreover, Nicoloff et al. identified a large tandem"/>
   <result pre="acrAB locus in a mutant isolated in the presence of" exact="tetracycline" post="(32). Such a mutation was found to overexpress the"/>
   <result pre="or post-translational modifications. (D) Resistance mechanism of Mycobacterium tuberculosis to" exact="isoniazid" post="drug mutations in the katG gene causes the accumulation"/>
   <result pre="(rrs) for tetracyclines and aminoglycosides and 23S rRNA (rrl) for" exact="linezolid" post="(13). The clinical use of linezolid has selected S."/>
   <result pre="23S rRNA (rrl) for linezolid (13). The clinical use of" exact="linezolid" post="has selected S. pneumoniae (35) and S. aureus (36)"/>
   <result pre="pathogen (1.8 million in 2015) (42). Unfortunately, the resistance to" exact="isoniazid" post="(INH), one of the four antibiotics used for the"/>
   <result pre="the mycobacterial cell envelope (43). The mechanisms of action of" exact="isoniazid" post="are diverse and not fully known due to the"/>
   <result pre="resistant to streptogramins by mutation in ribosomal protein L22 during" exact="pristinamycin" post="therapy of Pneumococcal Pneumonia. J Antimicrob Chemother. (2007) 59:1010–2."/>
   <result pre="immunity. Sci Transl Med. (2011) 3:91ra62. 10.1126/scitranslmed.300223421753121 97.TsaiCWMorrisS. Approval of" exact="raxibacumab" post="for the treatment of inhalation anthrax under the US"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="4-part\PMC7286216\results\search\drugs\results.xml">
   <result pre="therapeutics used to treat HEV infection include the nucleoside analog" exact="ribavirin" post="and interferon-α (IFN-α). Ribavirin therapy can be fairly efficient"/>
   <result pre="as nutritional status, including micronutrient deficiencies and the lack of" exact="folic acid," post="may also influence the immune response to HEV infection"/>
   <result pre="levels of hormonal factors, such as progesterone, estrogen and human" exact="chorionic gonadotropin" post="(HCG), change dramatically and are considerably higher than at"/>
   <result pre="FHF patients than in HEV-negative patients or controls [104]. Increased" exact="estradiol" post="in the serum of HEV-infected pregnant women promoted viral"/>
   <result pre="modulation of the immune system. For example, high levels of" exact="progesterone" post="and estrogen can alter the balance between Th1 and"/>
   <result pre="embryocidal and teratogenic effects in animals [25, 132, 133] Thus," exact="ribavirin" post="is not recommended for use in pregnant women. IFN-α"/>
   <result pre="recommended to be administered to pregnant women [23, 24]. Recently," exact="sofosbuvir" post="showed antiviral activity against HEV both in vitro and"/>
   <result pre="culture [139, 140]. However, more controlled studies are needed before" exact="sofosbuvir" post="can be recommended for HEV infection in pregnancy. For"/>
   <result pre="HSV Herpes simplex virus AVH Acute viral hepatitis HCG Human" exact="chorionic gonadotropin" post="PR Progesterone receptor PROGINS Progesterone receptor (PR) gene mutations"/>
   <result pre="hepatitis E virusAntivir Res201410210611824374149 24.KinastVBurkardTLTodtDSteinmannEHepatitis E virus drug developmentViruses2019116485 25.SinclairSMJonesJKMillerRKGreeneMFKwoPYMaddreyWCThe" exact="ribavirin" post="pregnancy registry: an interim analysis of potential teratogenicity at"/>
   <result pre="feto-maternal outcomesLiver Int20193963363929979823 117.BosePDDasBCKumarAGondalRKumarDKarPHigh viral load and deregulation of the" exact="progesterone" post="receptor signaling pathway: association with hepatitis E-related poor pregnancy"/>
   <result pre="E virus RNA polymerase promotes its replication and associates with" exact="ribavirin" post="treatment failure in organ transplant recipientsGastroenterology201414710081011.e100725181691 124.BorkakotiJAhmedGRaiAKarPReport of novel"/>
   <result pre="ORF3 protein may interrupt the blood coagulation processPLoS One20138e5632023418552 132.RobertsSSMillerRKJonesJKLindsayKLGreeneMFMaddreyWCWilliamsITLiuJSpiegelRJThe" exact="ribavirin" post="pregnancy registry: findings after 5 years of enrollment, 2003-2009Birth"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="4-part\PMC7286522\results\search\drugs\results.xml">
   <result pre="was further investigated in downstream studies. The inhibitory activities of" exact="bortezomib" post="were confirmed using different cellular models and CHIKV strains."/>
   <result pre="models and CHIKV strains. Time-of-addition and time-of-removal studies suggested that" exact="bortezomib" post="inhibited CHIKV at an early, post-entry stage of replication."/>
   <result pre="an early, post-entry stage of replication. In western blot analysis," exact="bortezomib" post="treatment resulted in a prominent decrease in structural protein"/>
   <result pre="protein ratios potentially being a contributing factor. Proteasome inhibitors like" exact="bortezomib" post="likely disrupt CHIKV replication through a variety of complex"/>
   <result pre="into its antiviral mechanism. We confirmed the anti-CHIKV effects of" exact="bortezomib" post="using different cell lines and CHIKV strains. We found"/>
   <result pre="using different cell lines and CHIKV strains. We found that" exact="bortezomib" post="resulted in a major decrease in levels of CHIKV"/>
   <result pre="increased CHIKV RNA synthesis. We propose that proteasome inhibitors like" exact="bortezomib" post="are likely to inhibit CHIKV through various mechanisms that"/>
   <result pre="a post-entry step in the CHIKV replication cycle. Treatment with" exact="bortezomib" post="also resulted in a decrease in structural protein expression."/>
   <result pre="effects of proteasome inhibitors, we tested the inhibitory potential of" exact="bortezomib" post="using CHIKV-infected BHK21 cells in both post-treatment and pre-treatment"/>
   <result pre="with bortezomib. This was performed to establish the effects of" exact="bortezomib" post="on post-entry steps. As seen in Fig 1A, treatment"/>
   <result pre="steps. As seen in Fig 1A, treatment with 0.1 μM" exact="bortezomib" post="onwards resulted in significant inhibition of CHIKV infectious titer."/>
   <result pre="1A), indicating minimal toxicity. In fact, treatment with 0.1 μM" exact="bortezomib" post="produced 97% (1.5 log10 units) inhibition with no decrease"/>
   <result pre="was also carried out, where BHK21 cells were treated with" exact="bortezomib" post="for 2 hours, washed with PBS and then immediately"/>
   <result pre="then immediately infected with CHIKV. This was to determine whether" exact="bortezomib" post="could affect the cells in a way that hindered"/>
   <result pre="entry. The inhibitory trend was not observed upon pre-treatment with" exact="bortezomib" post="(Fig 1B). Collectively, this data suggests that the anti-CHIKV"/>
   <result pre="1B). Collectively, this data suggests that the anti-CHIKV effects of" exact="bortezomib" post="are likely to occur at a post-entry stage in"/>
   <result pre="post-entry stage in the replication cycle. Fig 1 Effects of" exact="bortezomib" post="treatment on CHIKV infection in BHK21 cells. (A) BHK21"/>
   <result pre="were infected with CHIKV-122508 and treated with indicated concentrations of" exact="bortezomib" post="for 24h. CHIKV titers are presented in the bar"/>
   <result pre="control). (B) In pre-treatment assays, BHK21 cells were treated with" exact="bortezomib" post="for 2h, washed and infected with CHIKV-122508 at MOI"/>
   <result pre="to its inhibitory effects on macromolecular synthesis [39]. Treatment with" exact="carfilzomib" post="(Fig 2E) and oprozomib (Fig 2H) resulted in decreasing"/>
   <result pre="of (A) MG-132, (B) MLN-9708 (C) MLN-2238, (D) delanzomib, (E)" exact="carfilzomib" post="(F) ONX-0914, (G) epoxomicin, (H) oprozomib (I) lactacystin and"/>
   <result pre="comparing proteasome inhibitor-treated samples to vehicle control). Inhibitory effects of" exact="bortezomib" post="across different CHIKV strains and cell lines In order"/>
   <result pre="observed were not due to cell-line- or CHIKV strain-dependent effects," exact="bortezomib" post="was tested in two additional cell lines (HeLa and"/>
   <result pre="HSMM) and against two strains of CHIKV. In HeLa cells," exact="bortezomib" post="treatment resulted in a dose-dependent reduction of titer for"/>
   <result pre="with CHIKV-122508 and CHIKV-0708, respectively (Fig 3A). The efficacy of" exact="bortezomib" post="was also confirmed in primary human skeletal myoblasts (HSMM),"/>
   <result pre="in HSMM cells was inhibited in a dose-dependent manner upon" exact="bortezomib" post="treatment (Fig 3B). A maximal inhibition of 1.5 log10"/>
   <result pre="of &amp;gt;106 PFU/ml were obtained. Fig 3 Inhibitory effects of" exact="bortezomib" post="on different CHIKV strains and cell lines. (A) HeLa"/>
   <result pre="cells were infected with CHIKV-122508 or CHIKV-0708 and post-treated with" exact="bortezomib" post="for 24h. CHIKV titers are presented in the bar"/>
   <result pre="(B) HSMM cells were infected with CHIKV-122508 and post-treated with" exact="bortezomib" post="for 24h. CHIKV titers are presented in the bar"/>
   <result pre="ANOVA test and Dunnett’s post-test. 10.1371/journal.pntd.0008336.t001Table 1 Selectivity indices of" exact="bortezomib" post="treatment in BHK, HeLa and HSMM cells infected with"/>
   <result pre="to identify the window in the CHIKV replication cycle where" exact="bortezomib" post="exerts its effects. As displayed in the schematic diagram"/>
   <result pre="diagram in Fig 4A, time-of-addition experiments were performed by adding" exact="bortezomib" post="at different time-points post-infection, while time-of-removal experiments were conducted"/>
   <result pre="different time-points post-infection, while time-of-removal experiments were conducted by adding" exact="bortezomib" post="immediately after infection and removing it at different time-points"/>
   <result pre="time-points (0, 2, 4 hpi) are shown. For time-of-addition studies," exact="bortezomib" post="was added at different time-points post-infection. For time-of-removal studies,"/>
   <result pre="bortezomib was added at different time-points post-infection. For time-of-removal studies," exact="bortezomib" post="was added at 0h post-infection and then removed at"/>
   <result pre="harvested at 48 hpi. Dotted lines represent the duration of" exact="bortezomib" post="treatment. (B) CHIKV titers from time-of-addition and time-of-removal assays."/>
   <result pre="means from at least 4 replicates. The antiviral effect of" exact="bortezomib" post="was most pronounced when it was added at early"/>
   <result pre="inhibited (Fig 4B). The time-of-removal experiment revealed that removal of" exact="bortezomib" post="at 16 hpi or earlier prevented its inhibitory effects"/>
   <result pre="inhibitory effects (Fig 4B). Furthermore, time-of-removal studies also showed that" exact="bortezomib" post="treatment for the first 16h was necessary before its"/>
   <result pre="in structural protein levels We next evaluated the possibility that" exact="bortezomib" post="affects CHIKV RNA synthesis and/or viral RNA translation events."/>
   <result pre="time-points post-infection in HeLa cells. As shown in Fig 5," exact="bortezomib" post="treatment resulted in a striking decrease of about 50"/>
   <result pre="in a dose-dependent manner upon treatment with different concentrations of" exact="bortezomib" post="at 6 hpi (Fig 6). Fig 5 Time-point studies"/>
   <result pre="6). Fig 5 Time-point studies of CHIKV protein levels upon" exact="bortezomib" post="treatment. HeLa cells were infected with CHIKV-122508 and treated"/>
   <result pre="were infected with CHIKV-122508 and treated with either 0.1 μM" exact="bortezomib" post="or vehicle control. Protein samples were harvested at different"/>
   <result pre="protein). Fig 6 Dose-dependent studies of CHIKV protein levels upon" exact="bortezomib" post="treatment at 6 hpi. HeLa cells were infected with"/>
   <result pre="were infected with CHIKV-122508 and treated with either 0.1 μM" exact="bortezomib" post="or vehicle control. Protein samples were harvested at 6"/>
   <result pre="and nsP3 was observed upon treatment with increasing concentrations of" exact="bortezomib" post="(Fig 6). These fluctuations suggest that bortezomib may affect"/>
   <result pre="increasing concentrations of bortezomib (Fig 6). These fluctuations suggest that" exact="bortezomib" post="may affect structural and ns proteins in different ways,"/>
   <result pre="Western blot analysis showed major elevations in nsP4 levels upon" exact="bortezomib" post="treatment, especially at early time-points of 6 and 8"/>
   <result pre="(Fig 4B), which showed that the maximal inhibitory effect of" exact="bortezomib" post="was observed when added between 0 to 8 hpi."/>
   <result pre="transcripts for subsequent translation [47]. To understand the effects of" exact="bortezomib" post="treatment on eIF2α phosphorylation in CHIKV-infected cells, the levels"/>
   <result pre="eIF2α were measured in time-point studies. Fig 8 shows that" exact="bortezomib" post="treatment of CHIKV-infected HeLa cells caused a general reduction"/>
   <result pre="time, with relatively stable levels of total eIF2α. Strikingly, however," exact="bortezomib" post="treatment in mock-infected cells also resulted in reduced phospho-eIF2α"/>
   <result pre="bortezomib. Fig 8 Changes in total and phospho-eIF2α levels upon" exact="bortezomib" post="treatment. (A) HeLa cells were infected with CHIKV-122508 and"/>
   <result pre="were infected with CHIKV-122508 and treated with either 0.1 μM" exact="bortezomib" post="or vehicle control. Protein samples were harvested at different"/>
   <result pre="CHIKV ns protein levels, we also evaluated the effects of" exact="bortezomib" post="on CHIKV RNA levels. Bortezomib treatment increased total CHIKV"/>
   <result pre="at 12 hpi and 24 hpi (Fig 9B), suggesting that" exact="bortezomib" post="induces similar effects on replication of both CHIKV strands."/>
   <result pre="it is clear that the major direct antiviral effect of" exact="bortezomib" post="stems from its effect on suppressing structural protein levels,"/>
   <result pre="extensive study. Fig 9 Changes in CHIKV RNA levels upon" exact="bortezomib" post="treatment. HeLa cells were infected with CHIKV-122508 and treated"/>
   <result pre="were infected with CHIKV-122508 and treated with either 0.1 μM" exact="bortezomib" post="or vehicle control. Samples were harvested at different time-points"/>
   <result pre="and negative-sense CHIKV RNA. The major direct antiviral effect of" exact="bortezomib" post="is likely to result from its effect on suppressing"/>
   <result pre="in different ways. In previous studies, the antiviral effects of" exact="bortezomib" post="has been attributed to a number of different mechanisms."/>
   <result pre="mechanisms. In cells infected with Rift Valley Fever virus (RVFV)," exact="bortezomib" post="reduced the ability of the non-structural S-segment protein (NSs)"/>
   <result pre="with thrombocytopenia syndrome virus (SFTSV), a phlebovirus related to RVFV," exact="bortezomib" post="treatment reversed the degradation of RIG-I induced by the"/>
   <result pre="[24]. In our study, the increase in nsP4 levels upon" exact="bortezomib" post="treatment suggests that the CHIKV nsP4, like that of"/>
   <result pre="and nsP3 may be due to multiple competing effects of" exact="bortezomib" post="on these proteins. For instance, bortezomib may either increase"/>
   <result pre="multiple competing effects of bortezomib on these proteins. For instance," exact="bortezomib" post="may either increase nsP2/nsP3 expression or reduce their degradation,"/>
   <result pre="their levels within infected cells. However, by reducing virion production," exact="bortezomib" post="also restricts viral spread in the monolayer, reducing the"/>
   <result pre="hpi, despite increased nsP4 levels from 6 hpi onwards. While" exact="bortezomib" post="caused some increase in ns protein levels, structural protein"/>
   <result pre="and significantly decreased at all time-points. This may suggest that" exact="bortezomib" post="may affect SG RNA translation differently from G RNA"/>
   <result pre="G and SG RNA may explain the different effects of" exact="bortezomib" post="on CHIKV ns and structural proteins. A similar phenomenon"/>
   <result pre="similar possibility. In dose-dependent studies, treatment with 0.025 μM of" exact="bortezomib" post="caused CHIKV nsP3 levels to increase by about 30%"/>
   <result pre="concentrations. The alterations in ns and structural protein levels upon" exact="bortezomib" post="treatment also reflect a similar phenotype recently described for"/>
   <result pre="changes in their ratio, similar to what is observed during" exact="bortezomib" post="treatment, would have a negative impact on viral replication."/>
   <result pre="of proteasome inhibitors also inhibit other cellular proteases. For instance," exact="bortezomib" post="exhibits off-target activity against some intracellular proteases, including cathepsins"/>
   <result pre="from western blot studies showed that proteasome inhibitors apart from" exact="bortezomib" post="caused similar changes to CHIKV proteins, suggesting a common"/>
   <result pre="contributors to their inhibitory effects. Whether the antiviral effects of" exact="bortezomib" post="are a result of inhibition of translation of SG"/>
   <result pre="be used as CHIKV antivirals is warranted. A limitation of" exact="bortezomib" post="is its narrow therapeutic window [61]. In cancer patients,"/>
   <result pre="within two weeks. Furthermore, altering the route of administration of" exact="bortezomib" post="from intravenous to subcutaneous has been found to significantly"/>
   <result pre="a similar method could be employed to limit toxicity of" exact="bortezomib" post="and other proteasome inhibitors in the context of CHIKV"/>
   <result pre="pre-treatment assay was also performed, where cells were treated with" exact="bortezomib" post="prior to infection with CHIKV. BHK21 monolayers were incubated"/>
   <result pre="with CHIKV. BHK21 monolayers were incubated with various concentrations of" exact="bortezomib" post="for 2h at 37°C before being washed twice with"/>
   <result pre="-80°C prior to performing plaque assays for titration. Validation of" exact="bortezomib" post="activity in HeLa and HSMM Post-treatment experiments similar to"/>
   <result pre="[68]. After the washing step, infected cells were incubated with" exact="bortezomib" post="at various concentrations for 48h (HeLa) or 24h (HSMM)"/>
   <result pre="plaque assays. In order to measure the therapeutic window of" exact="bortezomib" post="in CHIKV-infected HeLa cells, the selectivity index (SI) was"/>
   <result pre="cytotoxic concentration) to EC50 (50% effective concentration). The EC50 of" exact="bortezomib" post="in HeLa cells was defined as the concentration of"/>
   <result pre="bortezomib in HeLa cells was defined as the concentration of" exact="bortezomib" post="required to reduce virus titer by 50%. The CC50"/>
   <result pre="by 50%. The CC50 was defined as the concentration of" exact="bortezomib" post="required to reduce cell viability by 50%. Cell viability"/>
   <result pre="and washed twice with PBS. For time-of-addition experiments, 0.1 μM" exact="bortezomib" post="was added at different time-points after the 1.5h infection"/>
   <result pre="different time-points after the 1.5h infection period. In time-of-removal experiments," exact="bortezomib" post="was added immediately after the 1.5h infection period and"/>
   <result pre="Studio programme. Measurement of changes in CHIKV RNA levels upon" exact="bortezomib" post="treatment HeLa cells were seeded on 24-well plates (80,000"/>
   <result pre="3 times with PBS before being incubated with 0.1 μM" exact="bortezomib" post="or vehicle control. Cells were washed once with PBS"/>
   <result pre="2013;73(1):45–54. 10.1007/s40265-013-0006-623338539 38BuacD, ShenM, SchmittS, KonaFR, DeshmukhR, ZhangZ, et al.From" exact="bortezomib" post="to other inhibitors of the proteasome and beyond.Curr Pharm"/>
   <result pre="ParlatiF, ShenkKD, LeeSJ, et al.Nonproteasomal targets of the proteasome inhibitors" exact="bortezomib" post="and carfilzomib: a link to clinical adverse events. Clin"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="4-part\PMC7288254\results\search\drugs\results.xml">
   <result pre="to active transport of the danger associated molecular pattern (DAMP)" exact="adenosine" post="triphosphate (ATP) out of the cell, resulting in immunogenic"/>
   <result pre="of immunotherapy drugsNat. Rev. Drug Discov.20151464266226323545 15.HodiFSet al.Improved survival with" exact="ipilimumab" post="in patients with metastatic melanomaN. Engl. J. Med201036371172320525992 16.CarboneDPet"/>
   <result pre="in patients with metastatic melanomaN. Engl. J. Med201036371172320525992 16.CarboneDPet al.First-line" exact="nivolumab" post="in stage IV or recurrent non-small-cell lung cancerN. Engl."/>
   <result pre="lung cancerN. Engl. J. Med.20173762415242628636851 17.WolchokJDet al.Overall survival with combined" exact="nivolumab" post="and ipilimumab in advanced melanomaN. Engl. J. Med.20173771345135628889792 18.BarlesiFet"/>
   <result pre="Engl. J. Med.20173762415242628636851 17.WolchokJDet al.Overall survival with combined nivolumab and" exact="ipilimumab" post="in advanced melanomaN. Engl. J. Med.20173771345135628889792 18.BarlesiFet al.Avelumab versus"/>
   <result pre="ipilimumab in advanced melanomaN. Engl. J. Med.20173771345135628889792 18.BarlesiFet al.Avelumab versus" exact="docetaxel" post="in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN"/>
   <result pre="future opportunities and challenges. Curr. Oncol.10.3747/co.25.3840 (2018). 22.RittmeyerAet al.Atezolizumab versus" exact="docetaxel" post="in patients with previously treated non-small-cell lung cancer (OAK):"/>
   <result pre="measles virus therapyMol. Ther.2014221949195925156126 26.PuzanovIet al.Talimogene laherparepvec in combination with" exact="ipilimumab" post="in previously untreated, unresectable stage IIIB-IV melanomaJ. Clin. Oncol.2016342619262627298410"/>
   <result pre="virotherapy for cancer therapyOncolytic Viroth20154183191 117.HamanoSet al.Oncolytic reovirus combined with" exact="trastuzumab" post="enhances antitumor efficacy through TRAIL signaling in human HER2-positive"/>
   <result pre="human HER2-positive gastric cancer cellsCancer Lett.201535684685425444894 118.LaengleJet al.Histone deacetylase inhibitors" exact="valproic acid" post="and vorinostat enhance trastuzumab-mediated antibody-dependent cell-mediated phagocytosisJ. Immunother. Cancer20208e00019531940587"/>
   <result pre="cancer cellsCancer Lett.201535684685425444894 118.LaengleJet al.Histone deacetylase inhibitors valproic acid and" exact="vorinostat" post="enhance trastuzumab-mediated antibody-dependent cell-mediated phagocytosisJ. Immunother. Cancer20208e00019531940587 119.PetricevicBet al.Trastuzumab"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="4-part\PMC7289343\results\search\drugs\results.xml">
   <result pre="RezzaG, AntonelliG. Antiviral activity of the combination of interferon and" exact="ribavirin" post="against chikungunya virus: are the results conclusive?J Infect Dis."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="4-part\PMC7290441\results\search\drugs\results.xml">
   <result pre="the antiviral activity of its chemical analogues, we found that" exact="ifenprodil" post="and clenbuterol also had reliable inhibitory effects against A/H1N1"/>
   <result pre="activity of its chemical analogues, we found that ifenprodil and" exact="clenbuterol" post="also had reliable inhibitory effects against A/H1N1 strains. Field-based"/>
   <result pre="release of progeny viruses from infected cells. Adamantanes such as" exact="amantadine" post="and rimantadine attenuate M2 proton channel activity, which is"/>
   <result pre="progeny viruses from infected cells. Adamantanes such as amantadine and" exact="rimantadine" post="attenuate M2 proton channel activity, which is required for"/>
   <result pre="using its chemical derivatives, we found that two additional analogues," exact="ifenprodil" post="and clenbuterol, reliably inhibited H1N1 isolates of the influenza"/>
   <result pre="Effect (CPE) Reduction Assay The test compounds nylidrin hydrochloride (~95%)," exact="ifenprodil" post="(+)–tartrate salt (≥98%), labetalol hydrochloride (≥98%), ritodrine hydrochloride (99.6%),"/>
   <result pre="The test compounds nylidrin hydrochloride (~95%), ifenprodil (+)–tartrate salt (≥98%)," exact="labetalol" post="hydrochloride (≥98%), ritodrine hydrochloride (99.6%), fenoterol hydrobromide (≥98%), eliprodil"/>
   <result pre="nylidrin hydrochloride (~95%), ifenprodil (+)–tartrate salt (≥98%), labetalol hydrochloride (≥98%)," exact="ritodrine" post="hydrochloride (99.6%), fenoterol hydrobromide (≥98%), eliprodil (≥98%), clenbuterol hydrochloride"/>
   <result pre="ifenprodil (+)–tartrate salt (≥98%), labetalol hydrochloride (≥98%), ritodrine hydrochloride (99.6%)," exact="fenoterol" post="hydrobromide (≥98%), eliprodil (≥98%), clenbuterol hydrochloride (≥95%), and bambuterol"/>
   <result pre="hydrochloride (≥98%), ritodrine hydrochloride (99.6%), fenoterol hydrobromide (≥98%), eliprodil (≥98%)," exact="clenbuterol" post="hydrochloride (≥95%), and bambuterol hydrochloride (≥98%) were purchased from"/>
   <result pre="(99.6%), fenoterol hydrobromide (≥98%), eliprodil (≥98%), clenbuterol hydrochloride (≥95%), and" exact="bambuterol" post="hydrochloride (≥98%) were purchased from Sigma-Aldrich. As control compounds,"/>
   <result pre="were purchased from Sigma-Aldrich. As control compounds, the M2 inhibitor" exact="amantadine" post="hydrochloride (AMT; ≥98%) and the polymerase inhibitor ribavirin (RBV;"/>
   <result pre="M2 inhibitor amantadine hydrochloride (AMT; ≥98%) and the polymerase inhibitor" exact="ribavirin" post="(RBV; ≥98%) were also from Sigma-Aldrich. The NA inhibitor"/>
   <result pre="ribavirin (RBV; ≥98%) were also from Sigma-Aldrich. The NA inhibitor" exact="oseltamivir" post="carboxylate (OSV-C; ≥98%) was acquired from United States Biological"/>
   <result pre="basis of antiviral efficacy against A/H1N1 strains, nylidrin, ifenprodil, and" exact="clenbuterol" post="were defined as active compounds as they have selectivity"/>
   <result pre="a total volume of 50 μL. In another control group," exact="oseltamivir" post="phosphate (OSV-P [&amp;gt;98%], provided by Hanmi Pharmaceutical Co., Gyeonggi-di,"/>
   <result pre="antiviral activity (Supplementary Figure S1). In the CPE-based antiviral assay," exact="ifenprodil" post="was comparable to nylidrin, with EC50 values of 6.6"/>
   <result pre="against PR8 with an EC50 value of 9.4 μM, whereas" exact="labetalol" post="and eliprodil were only marginally effective against HK alone"/>
   <result pre="EC50 values above 44.0 μM. In contrast, ritodrine, fenoterol, and" exact="bambuterol" post="had no antiviral activity against any viral strains. In"/>
   <result pre="influenza A and B viruses (Table 2). Nylidrin, ifenprodil, and" exact="clenbuterol" post="were consistently effective against A/H1N1 strains, but their efficacy"/>
   <result pre="in influenza B-infected cells. As expected, the remaining two compounds," exact="labetalol" post="and eliprodil, had little effect against any of these"/>
   <result pre="53.1 μM). These results indicate that nylidrin and its analogues," exact="ifenprodil" post="and clenbuterol, can reliably inhibit the infection of H1N1"/>
   <result pre="phenyl ring (Figure 1B). Even though the completely inactive compounds," exact="ritodrine" post="and fenoterol, had main electrostatic regions similar to those"/>
   <result pre="had an extra positive electrostatic potential at the amino terminal" exact="phenol" post="ring, which may hinder their specific interaction with a"/>
   <result pre="resting conditions. Agonists trigger its activation, resulting in conversion of" exact="adenosine" post="triphosphate (ATP) into cyclic AMP (cAMP) by adenylate cyclase"/>
   <result pre="assays, not only nylidrin, but also other GPCR-regulatory molecules including" exact="ifenprodil" post="and clenbuterol exhibited antiviral activity against A/H1N1 and/or A/H3N2"/>
   <result pre="only nylidrin, but also other GPCR-regulatory molecules including ifenprodil and" exact="clenbuterol" post="exhibited antiviral activity against A/H1N1 and/or A/H3N2 strains with"/>
   <result pre="as a core skeleton (Figure 1) and explained why particularly" exact="ifenprodil" post="and clenbuterol were as potent as nylidrin. It was"/>
   <result pre="core skeleton (Figure 1) and explained why particularly ifenprodil and" exact="clenbuterol" post="were as potent as nylidrin. It was because they"/>
   <result pre="by subtype dependency on the antiviral efficacy: nylidrin, ifenprodil, and" exact="clenbuterol" post="were active against all A/H1N1 strains tested; in contrast,"/>
   <result pre="active against all A/H1N1 strains tested; in contrast, nylidrin and" exact="ifenprodil" post="were limitedly effective only against A/Hong Kong/8/1968 and A/Seoul/11/1988"/>
   <result pre="Exp. Ophthalmol.1987225333810.1007/BF021558012883089 19.ShinJ.S.KuK.B.JangY.YoonY.S.ShinD.KwonO.S.GoY.Y.KimS.S.BaeM.A.KimM.Comparison of anti-influenza virus activity and pharmacokinetics of" exact="oseltamivir" post="free base and oseltamivir phosphateJ. Microbiol.20175597998310.1007/s12275-017-7371-x29214495 20.JangY.LeeH.W.ShinJ.S.GoY.Y.KimC.ShinD.MalpaniY.HanS.B.JungY.S.KimM.Antiviral activity of"/>
   <result pre="anti-influenza virus activity and pharmacokinetics of oseltamivir free base and" exact="oseltamivir" post="phosphateJ. Microbiol.20175597998310.1007/s12275-017-7371-x29214495 20.JangY.LeeH.W.ShinJ.S.GoY.Y.KimC.ShinD.MalpaniY.HanS.B.JungY.S.KimM.Antiviral activity of KR-23502 targeting nuclear export"/>
   <result pre="systemBMC Biotechnol.2012126210.1186/1472-6750-12-6222989299 25.MittagT.W.TormayA.MessengerM.PodosS.M.Ocular hypotension in the rabbit. Receptor mechanisms of" exact="pirbuterol" post="and nylidrinInvest. Ophthalmol. Vis. Sci.1985261631692857689 26.LiggettS.B.Update on current concepts"/>
   <result pre="multiplicity of infection (MOI) of 0.001 in the presence of" exact="dimethyl sulfoxide" post="(DMSO; 0.2%, a delivery vehicle), nylidrin (1, 10 or"/>
   <result pre="0.2%, a delivery vehicle), nylidrin (1, 10 or 100 μM)," exact="oseltamivir" post="carboxylate (OSV-C; 10 μM), or ribavirin (RBV; 100 μM)."/>
   <result pre="10 or 100 μM), oseltamivir carboxylate (OSV-C; 10 μM), or" exact="ribavirin" post="(RBV; 100 μM). Each viral protein and α-actin, as"/>
   <result pre="c Selectivity index (ratio of CC50/EC50); d not determined; e" exact="amantadine" post="hydrochloride; f control compound; g ribavirin; h oseltamivir carboxylate."/>
   <result pre="determined; e amantadine hydrochloride; f control compound; g ribavirin; h" exact="oseltamivir" post="carboxylate. viruses-12-00581-t002_Table 2Table 2 Antiviral activity of nylidrin and"/>
   <result pre="c Selectivity index (ratio of CC50/EC50); d not determined; e" exact="amantadine" post="hydrochloride; f ribavirin; g oseltamivir carboxylate."/>
   <result pre="CC50/EC50); d not determined; e amantadine hydrochloride; f ribavirin; g" exact="oseltamivir" post="carboxylate."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="4-part\PMC7290740\results\search\drugs\results.xml">
   <result pre="the Chinese Academy of Sciences (WIVA08201601). Mice were anesthetized with" exact="pentobarbital" post="sodium and then infected with the influenza virus through"/>
   <result pre="rate, respectively (Figure 4A,C,D). Whereas treatment with the reference drug" exact="oseltamivir" post="at 20 mg/kg/d protected 80% of mice from death"/>
   <result pre="However, the efficacy of EEC is not as good as" exact="oseltamivir" post="(data not shown), but comparable to that of ribavirin"/>
   <result pre="as oseltamivir (data not shown), but comparable to that of" exact="ribavirin" post="(Figure S1). In addition to human influenza A viruses"/>
   <result pre="can be found at https://www.mdpi.com/1999-4915/12/5/557/s1. Figure S1: Antiviral effects of" exact="ribavirin" post="against influenza virus PR 8 were determined in A"/>
   <result pre="105TCID50/mL was mixed with 5 μL of serially diluted EEC," exact="ribavirin" post="or oseltamivir, respectively. Each reaction was conducted at 37"/>
   <result pre="ratio of CC50/IC50. a A/PuertoRico/8/1934 (H1N1); b A/PuertoRico/8/1934 (H1N1, H274Y," exact="oseltamivir" post="resistant); c A/Human/Hubei/1/2009(H1N1); d A/human/Hubei/3/2005(H3N2);.e A/Duck/Hubei/216/1983(H7N8); f B/human/Hubei/1/2007."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="4-part\PMC7291249\results\search\drugs\results.xml">
   <result pre="virus-infected lungs [124]. These cells induce the robust production of" exact="nitric oxide" post="synthase 2, and deficiency in CCR2 leads to attenuation"/>
   <result pre="Biol.20101753053810.1038/nsmb.177920383144 38.LiS.SiebenC.LudwigK.HoferC.T.ChiantiaS.HerrmannA.EghiaianF.SchaapI.A.pH-Controlled two-step uncoating of influenza virusBiophys. J.20141061447145610.1016/j.bpj.2014.02.01824703306 39.GrambasS.BennettM.S.HayA.J.Influence of" exact="amantadine" post="resistance mutations on the pH regulatory function of the"/>
   <result pre="activity of influenza A virus M2 protein: Characterization of the" exact="amantadine" post="blockJ. Virol.1993675585559410.1128/JVI.67.9.5585-5594.19937688826 41.DiasA.BouvierD.CrepinT.McCarthyA.A.HartD.J.BaudinF.CusackS.RuigrokR.W.The cap-snatching endonuclease of influenza virus polymerase"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="4-part\PMC7293210\results\search\drugs\results.xml">
   <result pre="Serum was obtained by submandibular bleeding or heart puncture under" exact="isoflurane" post="anesthesia. Spleens were removed aseptically during necropsy after cervical"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="4-part\PMC7302680\results\search\drugs\results.xml">
   <result pre="10.1097/MD.000000000002058320583 : 4900: Research ArticleObservational Study Efficacy and safety of" exact="telbivudine" post="treatment for the prevention of HBV perinatal transmission RenCuicuiMDaWangLiliMDbSunWeihuiMDcMaLeiMDcDongZhiMDcHaoAnhuaMDcZhouLinMDcLiFengzhuMDcMaWenjieMDd∗"/>
   <result pre="the journal. http://creativecommons.org/licenses/by-nc/4.0medi-99-e20583.pdf Abstract Abstract To observe the efficacy of" exact="telbivudine" post="in chronic hepatitis B (CHB) women with high viral"/>
   <result pre="A total of 87 patients were included. Forty-two patients received" exact="telbivudine" post="orally 600 mg per day and treatment initiated from 12"/>
   <result pre="both serum HBV DNA and ALT in patients who received" exact="telbivudine" post="were significantly decreased at the 12th week after delivery,"/>
   <result pre="(P &amp;lt; .01). No significant changes were observed in patients not receiving" exact="telbivudine" post="(P &amp;gt; .05). Serum HBV DNA and ALT levels at the"/>
   <result pre="ALT levels at the 12th week after delivery in the" exact="telbivudine" post="group were significantly lower than those of patients without"/>
   <result pre="telbivudine group were significantly lower than those of patients without" exact="telbivudine" post="(P &amp;lt; .01). The serum HBsAg-positive rate in neonates 7 months"/>
   <result pre="Both mental and physical development in neonates with exposure to" exact="telbivudine" post="during perinatal period were similar to those without telbivudine"/>
   <result pre="to telbivudine during perinatal period were similar to those without" exact="telbivudine" post="exposure. Keywords Hepatitis B virus long-term efficacy and safety"/>
   <result pre="Hepatitis B virus long-term efficacy and safety mother-neonatal transmission pregnancy" exact="telbivudine" post="1 Introduction Chronic hepatitis B virus (CHB) infection remains"/>
   <result pre="besides HBIg and HBV vaccination.[5] The previous study showed that" exact="telbivudine" post="(LdT) was effective to reduce serum HBV DNA in"/>
   <result pre="was mainly to evaluate the efficacy and safety profile of" exact="telbivudine" post="in pregnant women with high HBV load and the"/>
   <result pre="Table 1 Clinical characteristics of patients enrolled. 3.2 Efficacy of" exact="telbivudine" post="in mothers At the time of delivery, the mean"/>
   <result pre="infants in all groups at month 7. 3.4 Safety of" exact="telbivudine" post="in infants No significant difference was observed between infants"/>
   <result pre="indicated that their intelligence developments were not affected by perinatal" exact="telbivudine" post="exposure, compared with infants from control groups as shown"/>
   <result pre="and guidelines to improve MTCT prevention. Previous advances showed that" exact="telbivudine" post="had no effects on human nucleotides stability or DNA"/>
   <result pre="involving 3622 pregnant CHB women, showed that LdT, LAM, or" exact="tenofovir" post="was effective to reduce MTCT rate with no significant"/>
   <result pre="adverse maternal or fetal events.[19] Consistently, our study indicated that" exact="telbivudine" post="treatment during pregnancy in women with high viral load"/>
   <result pre="= polymerase chain reaction, SD = standard deviation, TDF =" exact="tenofovir" post="disoproxil. How to cite this article: Ren C, Wang"/>
   <result pre="Zhou L, Li F, Ma W. Efficacy and safety of" exact="telbivudine" post="treatment for the prevention of HBV perinatal transmission. Medicine."/>
   <result pre="of pegylated interferon monotherapy and de novo pegylated interferon plus" exact="tenofovir" post="combination therapy in patients with chronic hepatitis B. Infect"/>
   <result pre="[7]YiWLiMHXieYet al.Prospective cohort study on the efficacy and safety of" exact="telbivudine" post="used throughout pregnancy in blocking mother-to-child transmission of hepatitis"/>
   <result pre="Soc2018;7:290–5.28992071 [10]LimSSLiaoHTTsaiCYTelbivudine associated mitochondrial myopathy. Liver Int2018;38:1139.29570939 [11]ZhangHPanCQPangQet al.Telbivudine or" exact="lamivudine" post="use in late pregnancy safely reduces perinatal transmission of"/>
   <result pre="virus in real-life practice. Hepatology2014;60:468–76.25187919 [12]HuYXuCXuBet al.Safety and efficacy of" exact="telbivudine" post="in late pregnancy to prevent mother-to-child transmission of hepatitis"/>
   <result pre="prospective and open-label study for the efficacy and safety of" exact="telbivudine" post="in pregnancy for the prevention of perinatal transmission of"/>
   <result pre="B virus infection. J Hepatol2011;55:1215–21.21703206 [16]HanGRJiangHXYueXet al.Efficacy and safety of" exact="telbivudine" post="treatment: an open-label, prospective study in pregnant women for"/>
   <result pre="gestational stages for the prevention of mother-to-child transmission: Outcomes of" exact="telbivudine" post="treatment during pregnancy. Medicine (Baltimore)2016;95:e4847.27749537 [19]BrownRJMcMahonBJLokASet al.Antiviral therapy in"/>
   <result pre="[21]ZhouCYuYYangQet al.Motor development delay in offspring is associated with prenatal" exact="telbivudine" post="exposure. Medicine (Baltimore)2018;97:e0053.29489662"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="4-part\PMC7310742\results\search\drugs\results.xml">
   <result pre="infection on day 7[33]. Mice were lightly anesthetized with 2.5%" exact="isoflurane" post="and IAV or GAS was given intranasally (100 μl"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="4-part\PMC7325039\results\search\drugs\results.xml">
   <result pre="count (0.0 × 109/L) were significantly downregulated. Treatment with valacyclovir, ebastine, mecobalamine," exact="pregabalin" post="and calamine lotion for 5 days was effective therapy for"/>
   <result pre="(Supplementary Table S1). The patient was prescribed valacyclovir, ebastine, mecobalamine," exact="pregabalin" post="and calamine lotion. The vesicles became crusts and then"/>
  </snippets>
 </snippetsTree>
</projectSnippetsTree>
